<!DOCTYPE html>



<html lang="en">



	<meta charset="UTF-8">

	<meta name="viewport" content="width=device-width, initial-scale=1.0">

	<style>


    .node {

        stroke: #fff;

        stroke-width: 2px;

    }

    

    .link {

        stroke: #777;

        stroke-width: 2px;

    }



</style>

<body>

<a href="https://riskrunners.com">Home</a><br>




<a href="#risk_factors">Jump to Risk Factors</a><br>



<a href="#industry">Jump to Industries</a><br>


<a href="#exposure">Jump to Exposures</a><br>


<a href="#event_code">Jump to Event Codes</a><br>


<a href="#wiki">Jump to Wiki Summary</a><br><br>


    <script src="https://d3js.org/d3.v3.min.js"></script>

    <script>


// set a width and height for our SVG

var width = 3000,


    height = 3000;

    
// setup links

var links =     [
{source: "START_HERE", target: "3: following risks actually", fill: "#b666d2"},
{source: "3: following risks actually", target: "3: financial condition", fill: "#b666d2"},
{source: "3: financial condition", target: "3: operations", fill: "#b666d2"},
{source: "3: operations", target: "3: future growth prospects could", fill: "#b666d2"},
{source: "3: future growth prospects could", target: "3: materially", fill: "#b666d2"},
{source: "3: materially", target: "3: adversely affected", fill: "#b666d2"},
{source: "3: following risks actually", target: "4: circumstances", fill: "#701c1c"},
{source: "4: circumstances", target: "4: trading price", fill: "#701c1c"},
{source: "4: trading price", target: "4: common stock could decline", fill: "#701c1c"},
{source: "4: common stock could decline", target: "4: investment", fill: "#701c1c"},
{source: "4: circumstances", target: "19: establishment", fill: "#fe2712"},
{source: "19: establishment", target: "19: development", fill: "#fe2712"},
{source: "19: development", target: "19: distribution", fill: "#fe2712"},
{source: "19: distribution", target: "19: sales force", fill: "#fe2712"},
{source: "19: establishment", target: "20: intense competition", fill: "#0014a8"},
{source: "20: intense competition", target: "20: additional qualified sales representatives", fill: "#0014a8"},
{source: "20: additional qualified sales representatives", target: "20: independent sales", fill: "#0014a8"},
{source: "20: intense competition", target: "24: pressure from", fill: "#9acd32"},
{source: "24: pressure from", target: "24: competitors", fill: "#9acd32"},
{source: "24: competitors", target: "24: medical reimbursement", fill: "#9acd32"},
{source: "24: medical reimbursement", target: "24: products at prices necessary", fill: "#9acd32"},
{source: "24: products at prices necessary", target: "24: operations", fill: "#9acd32"},
{source: "24: operations", target: "24: reach profitability", fill: "#9acd32"},
{source: "24: pressure from", target: "26: technologies", fill: "#fffaf0"},
{source: "26: technologies", target: "26: established companies", fill: "#fffaf0"},
{source: "26: established companies", target: "26: competitive pressure", fill: "#fffaf0"},
{source: "26: technologies", target: "34: legislation regulation", fill: "#a0785a"},
{source: "34: legislation regulation", target: "34: reimbursement", fill: "#a0785a"},
{source: "34: reimbursement", target: "34: existing products", fill: "#a0785a"},
{source: "34: existing products", target: "34: products currently under development", fill: "#a0785a"},
{source: "34: products currently under development", target: "34: products on", fill: "#a0785a"},
{source: "34: products on", target: "34: profitable basis", fill: "#a0785a"},
{source: "34: legislation regulation", target: "37: highly competitive market", fill: "#ffe135"},
{source: "37: highly competitive market", target: "37: face competition from", fill: "#ffe135"},
{source: "37: face competition from", target: "37: manufacturers as well as new market", fill: "#ffe135"},
{source: "37: highly competitive market", target: "43: of Contents ", fill: "#7c4848"},
{source: "43: of Contents ", target: "43: competitors", fill: "#7c4848"},
{source: "43: competitors", target: "43: either publicly traded", fill: "#7c4848"},
{source: "43: either publicly traded", target: "43: subsidiaries", fill: "#7c4848"},
{source: "43: subsidiaries", target: "43: publicly traded companies", fill: "#7c4848"},
{source: "43: publicly traded companies", target: "43: enjoy several competitive advantages over us", fill: "#7c4848"},
{source: "43: enjoy several competitive advantages over us", target: "43: significantly greater name recognition", fill: "#7c4848"},
{source: "43: significantly greater name recognition", target: "43: established relations with spine surgeons hospitals", fill: "#7c4848"},
{source: "43: established relations with spine surgeons hospitals", target: "43: thirdparty payors", fill: "#7c4848"},
{source: "43: thirdparty payors", target: "43: distribution networks with significant", fill: "#7c4848"},
{source: "43: distribution networks with significant", target: "43: international presence", fill: "#7c4848"},
{source: "43: international presence", target: "43: products supported by longterm clinical data", fill: "#7c4848"},
{source: "43: products supported by longterm clinical data", target: "43: United States Food ", fill: "#7c4848"},
{source: "43: United States Food ", target: "43: Drug Administration or FDA ", fill: "#7c4848"},
{source: "43: Drug Administration or FDA ", target: "43: regulatory approvals", fill: "#7c4848"},
{source: "43: regulatory approvals", target: "43: clearances", fill: "#7c4848"},
{source: "43: clearances", target: "43: product enhancements", fill: "#7c4848"},
{source: "43: product enhancements", target: "43: expansive portfolios", fill: "#7c4848"},
{source: "43: expansive portfolios", target: "43: intellectual property rights", fill: "#7c4848"},
{source: "43: intellectual property rights", target: "43: product research", fill: "#7c4848"},
{source: "43: product research", target: "43: development sales", fill: "#7c4848"},
{source: "43: development sales", target: "43: litigation", fill: "#7c4848"},
{source: "43: of Contents ", target: "44: spine industry", fill: "#0ff"},
{source: "44: spine industry", target: "44: becoming increasingly", fill: "#0ff"},
{source: "44: becoming increasingly", target: "44: new market entrants", fill: "#0ff"},
{source: "44: new market entrants", target: "44: at least partially by spine", fill: "#0ff"},
{source: "44: spine industry", target: "46: companies become successful", fill: "#ffb7c5"},
{source: "46: companies become successful", target: "46: competition", fill: "#ffb7c5"},
{source: "46: competition", target: "46: will become even", fill: "#ffb7c5"},
{source: "46: will become even", target: "46: intense leading", fill: "#ffb7c5"},
{source: "46: intense leading", target: "46: greater pricing", fill: "#ffb7c5"},
{source: "46: greater pricing", target: "46: difficult", fill: "#ffb7c5"},
{source: "46: companies become successful", target: "69: dependent on single source suppliers", fill: "#555d50"},
{source: "69: dependent on single source suppliers", target: "69: manufacturers", fill: "#555d50"},
{source: "69: manufacturers", target: "69: components", fill: "#555d50"},
{source: "69: components", target: "69: inability", fill: "#555d50"},
{source: "69: inability", target: "69: supply us with", fill: "#555d50"},
{source: "69: supply us with", target: "69: adequate supply", fill: "#555d50"},
{source: "69: adequate supply", target: "69: materials could harm", fill: "#555d50"},
{source: "69: dependent on single source suppliers", target: "86: interruption", fill: "#f08080"},
{source: "86: interruption", target: "86: additional", fill: "#f08080"},
{source: "86: additional", target: "86: allograft implants could significantly harm", fill: "#f08080"},
{source: "86: allograft implants could significantly harm", target: "86: revenues which could", fill: "#f08080"},
{source: "86: revenues which could", target: "86: market price", fill: "#f08080"},
{source: "86: market price", target: "86: common stock", fill: "#f08080"},
{source: "86: interruption", target: "START_HERE", fill: "#f08080"}]; 
    // create empty nodes array
    var nodes = {};
	var colorFill = [];
	
    // compute nodes from links data
    links.forEach(function(link) {
        link.source = nodes[link.source] ||
            (nodes[link.source] = {name: link.source});
        link.target = nodes[link.target] ||
            (nodes[link.target] = {name: link.target});
		colorFill.push({name: link.source.name, fill: link.fill });
		colorFill.push({name: link.target.name, fill: link.fill });
    });
	
	console.log(colorFill);


    // add a SVG to the body for our viz
    var svg=d3.select('body').append('svg')
        .attr("viewBox", "0 0 " + width + " " + height );

    // use the force
    var force = d3.layout.force()
		.charge(-5000)
		.gravity(0.3)
        .size([width, height])
        .nodes(d3.values(nodes))
        .links(links)
        .on("tick", tick)
        .linkDistance(200)
        .start();

    // add links
    var link = svg.selectAll('.link')
        .data(links)
        .enter().append('line')
        .attr('class', 'link'); 

    // add nodes
    var node = svg.selectAll('.node')
        .data(force.nodes())
        .enter().append('circle')
        .attr('class', 'node')
        .attr('r', width * 0.0035)
		.style("fill", function(d) {
									for (var i = 0; i < colorFill.length; i++) {
										//console.log(d.name);
										if(colorFill[i].name == d.name){
											console.log(colorFill[i].fill);
											return colorFill[i].fill;
										}
									} return "#555";
									
									});
	var label = svg.selectAll(null)
		.data(force.nodes())
		.enter()
		.append("text")
		.text(function (d) { return d.name; })
		.style("text-anchor", "middle")
		.style("fill", "#555")
		.style("font-family", "Arial")
		.style("font-size", 34);


    // what to do 
    function tick(e) {
        
        node.attr('cx', function(d) { return d.x = Math.max(6, Math.min(width - 6, d.x)); })
            .attr('cy', function(d) { return d.y = Math.max(6, Math.min(height - 6, d.y)); })
            .call(force.drag);
            
        link.attr('x1', function(d) { return d.source.x; })
            .attr('y1', function(d) { return d.source.y; })
            .attr('x2', function(d) { return d.target.x; })
            .attr('y2', function(d) { return d.target.y; });
		
		label.attr("x", function(d){ return d.x; })
             .attr("y", function (d) {return d.y - 10; });
        
    }
    
</script><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='industry'>Industries</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Investment Banking and Brokerage</td>
    </tr>
    <tr>
      <td>Health Care Distribution and Services</td>
    </tr>
    <tr>
      <td>Health Care Facilities</td>
    </tr>
    <tr>
      <td>Health Care Supplies</td>
    </tr>
    <tr>
      <td>Health Care</td>
    </tr>
    <tr>
      <td>Health Care Equipment and Services</td>
    </tr>
    <tr>
      <td>Managed Health Care</td>
    </tr>
    <tr>
      <td>Technology Hardware Storage and Peripherals</td>
    </tr>
    <tr>
      <td>Information Technology</td>
    </tr>
    <tr>
      <td>Technology Hardware and Equipment</td>
    </tr>
    <tr>
      <td>Automobile Manufacturers</td>
    </tr>
    <tr>
      <td>Motorcycle Manufacturers</td>
    </tr>
    <tr>
      <td>Automobiles and Components</td>
    </tr>
    <tr>
      <td>Electrical Components and Equipment</td>
    </tr>
    <tr>
      <td>Independent Power Producers and Energy Traders</td>
    </tr>
    <tr>
      <td>Application Software</td>
    </tr>
    <tr>
      <td>Asset Management and Custody Banks</td>
    </tr>
    <tr>
      <td>Research and Consulting Services</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='exposure'>Exposures</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Economic</td>
    </tr>
    <tr>
      <td>Military</td>
    </tr>
    <tr>
      <td>Regime</td>
    </tr>
    <tr>
      <td>Ease</td>
    </tr>
    <tr>
      <td>Express intent</td>
    </tr>
    <tr>
      <td>Judicial</td>
    </tr>
    <tr>
      <td>Intelligence</td>
    </tr>
    <tr>
      <td>Political reform</td>
    </tr>
    <tr>
      <td>Provide</td>
    </tr>
    <tr>
      <td>Rights</td>
    </tr>
    <tr>
      <td>Cooperate</td>
    </tr>
    <tr>
      <td>Crime</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='event_code'>Event Codes</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Military blockade</td>
    </tr>
    <tr>
      <td>Solicit support</td>
    </tr>
    <tr>
      <td>Yield to order</td>
    </tr>
    <tr>
      <td>Force</td>
    </tr>
    <tr>
      <td>Warn</td>
    </tr>
    <tr>
      <td>Accident</td>
    </tr>
    <tr>
      <td>Vote</td>
    </tr>
    <tr>
      <td>Sports contest</td>
    </tr>
    <tr>
      <td>Release or return</td>
    </tr>
    <tr>
      <td>Yield</td>
    </tr>
    <tr>
      <td>Host meeting</td>
    </tr>
    <tr>
      <td>Demand</td>
    </tr>
    <tr>
      <td>Complain</td>
    </tr>
    <tr>
      <td>Reward</td>
    </tr>
    <tr>
      <td>Acknowledge responsibility</td>
    </tr>
    <tr>
      <td>Grant</td>
    </tr>
    <tr>
      <td>Propose</td>
    </tr>
    <tr>
      <td>Adjust</td>
    </tr>
    <tr>
      <td>Sanction</td>
    </tr>
    <tr>
      <td>Agree</td>
    </tr>
    <tr>
      <td>Request</td>
    </tr>
    <tr>
      <td>Yield position</td>
    </tr>
    <tr>
      <td>Psychological state</td>
    </tr>
    <tr>
      <td>Accuse</td>
    </tr>
    <tr>
      <td>Reduce routine activity</td>
    </tr>
    <tr>
      <td>Reject</td>
    </tr>
    <tr>
      <td>Human death</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='wiki'>Wiki</th>
      <th>Wiki Summary</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Arithmetic">Arithmetic</a></td>
      <td>Arithmetic (from Ancient Greek  ἀριθμός (arithmós) 'number', and  τική [τέχνη] (tikḗ [tékhnē]) 'art, craft') is an elementary part of mathematics that consists of the study of the properties of the traditional operations on numbers—addition, subtraction, multiplication, division, exponentiation, and extraction of roots. In the 19th century, Italian mathematician Giuseppe Peano formalized arithmetic with his Peano axioms, which are highly important to the field of mathematical logic today.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Bitwise_operation">Bitwise operation</a></td>
      <td>In computer programming, a bitwise operation operates on a bit string, a bit array or a binary numeral (considered as a bit string) at the level of its individual bits. It is a fast and simple action, basic to the higher-level arithmetic operations and directly supported by the processor.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Special_Activities_Center">Special Activities Center</a></td>
      <td>The Special Activities Center (SAC) is a division of the Central Intelligence Agency responsible for covert operations and paramilitary operations. The unit was named Special Activities Division (SAD) prior to 2015.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operations_management">Operations management</a></td>
      <td>Operations management is an area of management concerned with designing and controlling the process of production and redesigning business operations in the production of goods or services. It involves the responsibility of ensuring that business operations are efficient in terms of using as few resources as needed and effective in meeting customer requirements.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operations_research">Operations research</a></td>
      <td>Operations research (British English: operational research), often shortened to the initialism OR, is a discipline that deals with the development and application of advanced analytical methods to improve decision-making. It is sometimes considered to be a subfield of mathematical sciences.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Surgery">Surgery</a></td>
      <td>Surgery is a medical or dental specialty that uses operative manual and instrumental techniques on a person to investigate or treat a pathological condition such as a disease or injury, to help improve bodily function, appearance, or to repair unwanted ruptured areas.\nThe act of performing surgery may be called a surgical procedure, operation, or simply "surgery".</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operation_(mathematics)">Operation (mathematics)</a></td>
      <td>In mathematics, an operation is a function which takes zero or more input values (called operands) to a well-defined output value. The number of operands (also known as arguments) is the arity of the operation.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Emergency_operations_center">Emergency operations center</a></td>
      <td>An emergency operations center (EOC) is a central command and control facility responsible for carrying out the principles of emergency preparedness and emergency management, or disaster management functions at a strategic level during an emergency, and ensuring the continuity of operation of a company, political subdivision or other organization.\nAn EOC is responsible for strategic direction and operational decisions and does not normally directly control field assets, instead leaving tactical decisions to lower commands.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Volatility_(finance)">Volatility (finance)</a></td>
      <td>In finance, volatility (usually denoted by σ) is the degree of variation of a trading price series over time, usually measured by the standard deviation of logarithmic returns.\nHistoric volatility measures a time series of past market prices.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Market_trend">Market trend</a></td>
      <td>A market trend is a perceived tendency of financial markets to move in a particular direction over time. These trends are classified as secular for long time frames, primary for medium time frames, and secondary for short time frames.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Arrested_Development">Arrested Development</a></td>
      <td>Arrested Development is an American television sitcom created by Mitchell Hurwitz, which originally aired on Fox for three seasons from  2003 to 2006, followed by a two-season revival on Netflix from 2013 to 2019. The show follows the Bluths, a formerly wealthy dysfunctional family.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Sustainable_development">Sustainable development</a></td>
      <td>Sustainable development is an organizing principle for meeting human development goals while also sustaining the ability of natural systems to provide the natural resources and ecosystem services on which the economy and society depend. The desired result is a state of society where living conditions and resources are used to continue to meet human needs without undermining the integrity and stability of the natural system.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Development/For!">Development/For!</a></td>
      <td>Development/For! (Latvian: Attīstībai/Par!, AP!) is a liberal political alliance in Latvia.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Software_development">Software development</a></td>
      <td>Software development is the process of conceiving, specifying, designing, programming, documenting, testing, and bug fixing involved in creating and maintaining applications, frameworks, or other software components. Software development involves writing and maintaining the source code, but in a broader sense, it includes all processes from the conception of the desired software through to the final manifestation of the software, typically in a planned and structured process.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Research_and_development">Research and development</a></td>
      <td>Research and development (R&amp;D or R+D), known in Europe as research and technological development (RTD), is the set of innovative activities undertaken by corporations or governments in developing new services or products, and improving existing ones. Research and development constitutes the first stage of development of a potential new service or the production process.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Prenatal_development">Prenatal development</a></td>
      <td>Prenatal development (from Latin  natalis 'relating to birth') includes the development of the embryo and of the foetus during a viviparous animal's gestation. Prenatal development starts with fertilization, in the germinal stage of embryonic development, and continues in fetal development until birth.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Competition">Competition</a></td>
      <td>Competition is a rivalry where two or more parties strive for a common goal which cannot be shared: where one's gain is the other's loss (an example of which is a zero-sum game). Competition can arise between entities such as organisms, individuals, economic and social groups, etc.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Competitor_backlinking">Competitor backlinking</a></td>
      <td>Competitor backlinking is a search engine optimization strategy that involves analyzing the backlinks of competing websites within a vertical search. The outcome of this activity is designed to increase organic search engine rankings and to gain an understanding of the link building strategies used by business competitors.By analyzing the backlinks to competitor websites, it is possible to gain a benchmark on the number of links and the quality of links that is required for high search engine rankings.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Competitors_for_the_Crown_of_Scotland">Competitors for the Crown of Scotland</a></td>
      <td>When the crown of Scotland became vacant in September 1290 on the death of the seven-year-old child Queen Margaret, 13 claimants to the throne came forward. Those with the most credible claims were John Balliol, Robert Bruce, John Hastings and Floris V, Count of Holland.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/List_of_female_fitness_and_figure_competitors">List of female fitness and figure competitors</a></td>
      <td>This is a list of female fitness and figure competitors.\n\n\n== A ==\nJelena Abbou\n\n\n== B ==\nLauren Beckham\nAlexandra Béres\nSharon Bruneau\n\n\n== C ==\nNatalie Montgomery-Carroll\nJen Cassetty\nKim Chizevsky\nSusie Curry\n\n\n== D ==\nDebbie Dobbins\nNicole Duncan\n\n\n== E ==\nJamie Eason\nAlexis Ellis\n\n\n== F ==\nAmy Fadhli\nJaime Franklin\n\n\n== G ==\nAdela García \nConnie Garner\nElaine Goodlad\nTracey Greenwood\nOksana Grishina\n\n\n== H ==\nMallory Haldeman\nVanda Hădărean\nJen Hendershott\nSoleivi Hernandez\nApril Hunter\n\n\n== I ==\n\n\n== J ==\nTsianina Joelson\n\n\n== K ==\nAdria Montgomery-Klein\nAshley Kaltwasser\n\n\n== L ==\nLauren Lillo\nMary Elizabeth Lado\nTammie Leady\nJennifer Nicole Lee\nAmber Littlejohn\nJulie Lohre\nJenny Lynn\n\n\n== M ==\nTimea Majorová\nLinda Maxwell\nDavana Medina\nJodi Leigh Miller\nChisato Mishima\n\n\n== N ==\nKim Nielsen\n\n\n== O ==\n\n\n== P ==\nVicky Pratt\nElena Panova\nChristine Pomponio-Pate\nCathy Priest\n\n\n== Q ==\n\n\n== R ==\nMaite Richert\nCharlene Rink\nKelly Ryan\n\n\n== S ==\nErin Stern\nCarol Semple-Marzetta\nKrisztina Sereny\nTrish Stratus (Patricia Anne Stratigias)\n\n\n== T ==\nKristi Tauti\nJennifer Thomas\n\n\n== U ==\n\n\n== V ==\nLisa Marie Varon\n\n\n== W ==\nLatisha Wilder\nTorrie Wilson\nLyen Wong\nJenny Worth\nNicole Wilkins\n\n\n== Y ==\n\n\n== Z ==\nMarietta Žigalová\nMalika Zitouni\n\n\n== See also ==\nList of female bodybuilders\n\n\n== References ==\nThere has been a rise in the number of women wanting to compete as fitness models.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Round-robin_tournament">Round-robin tournament</a></td>
      <td>A round-robin tournament (or all-play-all tournament) is a competition in which each contestant meets every other participant, usually in turn. A round-robin contrasts with an elimination tournament, in which participants are eliminated after a certain number of losses.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Price_discrimination">Price discrimination</a></td>
      <td>Price discrimination is a microeconomic pricing strategy where identical or largely similar goods or services are sold at different prices by the same provider in different markets. Price discrimination is distinguished from product differentiation by the more substantial difference in production cost for the differently priced products involved in the latter strategy.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Porter's_five_forces_analysis">Porter's five forces analysis</a></td>
      <td>Porter's Five Forces Framework is a method of analysing the operating environment of a competition of a business. It draws from industrial organization (IO) economics to derive five forces that determine the competitive intensity and, therefore, the attractiveness (or lack thereof) of an industry in terms of its profitability.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulation">Regulation</a></td>
      <td>Regulation is the management of complex systems according to a set of rules and trends. In systems theory, these types of rules exist in various fields of biology and society, but the term has slightly different meanings according to context.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/New_product_development">New product development</a></td>
      <td>In business and engineering, new product development (NPD) covers the complete process of bringing a new product to market, renewing an existing product or introducing a product in a new market. A central aspect of NPD is product design, along with various business considerations.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Timeline_of_Apple_Inc._products">Timeline of Apple Inc. products</a></td>
      <td>This timeline of Apple Inc. products is a list of all stand-alone Apple II, Macintosh, and other computers, as well as computer peripherals, expansion cards, ancillary products, and consumer electronics sold by Apple Inc.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Automotive_industry">Automotive industry</a></td>
      <td>The automotive industry comprises a wide range of companies and organizations involved in the design, development, manufacturing, marketing, and selling of motor vehicles. It is one of the world's largest industries by revenue (from 16 % such as in France up to 40 % to countries like Slovakia).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Intellectual_property">Intellectual property</a></td>
      <td>Intellectual property (IP) is a category of property that includes intangible creations of the human intellect. There are many types of intellectual property, and some countries recognize more than others.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Intellectual_property_infringement">Intellectual property infringement</a></td>
      <td>An intellectual property (IP) infringement is the infringement or violation of an intellectual property right. There are several types of intellectual property rights, such as copyrights, patents, trademarks, industrial designs, and trade secrets.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Market_structure">Market structure</a></td>
      <td>Market structure, in economics, depicts how firms are differentiated and categorised based on the types of goods they sell (homogeneous/heterogeneous) and how their operations are affected by external factors and elements. Market structure makes it easier to understand the characteristics of diverse markets.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Pricing_strategies">Pricing strategies</a></td>
      <td>A business can use a variety of pricing strategies when selling a product or service. To determine the most effective pricing strategy for a company, senior executives need to first identify the company's pricing position, pricing segment, pricing capability and their competitive pricing reaction strategy.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Manufacturing">Manufacturing</a></td>
      <td>Manufacturing is the creation or production of goods with the help of equipment, labor, machines, tools, and chemical or biological processing or formulation. It is the essence of secondary sector of the economy.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Market_power">Market power</a></td>
      <td>In economics, market power refers to the ability of a firm to influence the price at which it sells a product or service by manipulating either the supply or demand of the product or service to increase economic profit. In other words, market power occurs if a firm does not face a perfectly elastic demand curve and can set its price (P) above marginal cost (MC) without losing revenue.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Price_Chopper_and_Market_32_Supermarkets">Price Chopper and Market 32 Supermarkets</a></td>
      <td>Golub Corporation is an American supermarket operator. Headquartered in Schenectady, New York, it owns the chains Market 32 and Price Chopper Supermarkets.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Non-price_competition">Non-price competition</a></td>
      <td>Non-price competition is a marketing strategy "in which one firm tries to distinguish its product or service from competing products on the basis of attributes like design and workmanship". It often occurs in imperfectly competitive markets because it exists between two or more producers that sell goods and services at the same prices but compete to increase their respective market shares through non-price measures such as marketing schemes and greater quality.</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='risk_factors'>Risk Factors</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>NUVASIVE INC      Item 1A  Risk Factors             An <font color="blue">investment</font> in our <font color="blue"><font color="blue">common stock</font> involves</font> a high degree of risk</td>
    </tr>
    <tr>
      <td>You     should  consider <font color="blue">carefully</font> the risks and <font color="blue">uncertainties described</font> below     together with all other information contained or <font color="blue">incorporated by reference</font>     in this report before you decide to invest in our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>If any of     the <font color="blue">following risks actually</font> occurs, our business, <font color="blue">financial condition</font>,     results of <font color="blue">operations</font> and our <font color="blue">future growth prospects could</font> be <font color="blue">materially</font>     and <font color="blue"><font color="blue"><font color="blue">adversely</font> affect</font>ed</font></td>
    </tr>
    <tr>
      <td>Under these <font color="blue">circumstances</font>, the <font color="blue">trading price</font> of our     <font color="blue">common stock</font> could decline, and you may lose all or part of your <font color="blue">investment</font></td>
    </tr>
    <tr>
      <td>Risks Related to Our Business and Industry       Our failure to build an <font color="blue">effective</font> and <font color="blue">dedicated <font color="blue">distribution</font> network</font> for our     <font color="blue">products could</font> <font color="blue">significant</font>ly impair our ability to <font color="blue">increase sales</font> of our     products</td>
    </tr>
    <tr>
      <td>We have <font color="blue">only been selling</font> our products since 2001</td>
    </tr>
    <tr>
      <td>We <font color="blue">currently sell</font> a     <font color="blue">significant</font>  majority  of  our  products  in the <font color="blue">United States </font>through     <font color="blue"><font color="blue">distribution</font> arrangements with</font> a network of <font color="blue">in<font color="blue">dependent</font> agents</font> and sales     <font color="blue"><font color="blue">representatives</font> managed by</font> our <font color="blue">sales managers</font></td>
    </tr>
    <tr>
      <td>As a result, we are <font color="blue">dependent</font>     upon the sales and marketing efforts of our third-party sales agencies</td>
    </tr>
    <tr>
      <td>We     pay these agents and <font color="blue">sales <font color="blue">representatives</font></font> a <font color="blue">commission <font color="blue">based on</font></font> their     <font color="blue">product sales</font></td>
    </tr>
    <tr>
      <td>We are currently engaged in <font color="blue">significant</font> efforts to convince     agents and <font color="blue">sales <font color="blue">representatives</font></font> to <font color="blue"><font color="blue">exclusively</font> sell</font> our <font color="blue">spine surgery</font>     products</td>
    </tr>
    <tr>
      <td>We believe this is important in increasing our <font color="blue">product sales</font> as     <font color="blue">exclusivity brings greater focus from sales agents</font> and a <font color="blue">greater commitment</font>     to <font color="blue">generate sales</font> of our full <font color="blue">product line</font></td>
    </tr>
    <tr>
      <td>These efforts require us to     offer higher commissions, sometimes for <font color="blue">extended periods</font> of time</td>
    </tr>
    <tr>
      <td>As a     result, these efforts can result in <font color="blue">significant</font>ly increased expenses and may     therefore <font color="blue">negatively</font> impact our results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>In addition, if we     are unable to convince some of our established third-party sales agencies to     <font color="blue"><font color="blue">exclusively</font> sell</font> our <font color="blue">spine surgery</font> products, we would have to try to                                         17       _________________________________________________________________    [70]Table of <font color="blue">Contents       </font>transition this business to <font color="blue">exclusive agents</font></td>
    </tr>
    <tr>
      <td>There is a risk that sales     <font color="blue">revenue could</font> be lost in <font color="blue"><font color="blue">connection</font> with such</font> a transition</td>
    </tr>
    <tr>
      <td>Our efforts to build a <font color="blue">dedicated <font color="blue">sales force</font> also</font> include <font color="blue">initiatives</font>     to hire <font color="blue">sales <font color="blue">representatives</font></font> who work directly for us</td>
    </tr>
    <tr>
      <td>We have little     experience in <font color="blue">establishing</font> a <font color="blue">direct <font color="blue">sales force</font></font>, so there is a risk that     this <font color="blue"><font color="blue">sales force</font> will</font> not succeed in <font color="blue">growing sales</font> of our products</td>
    </tr>
    <tr>
      <td><font color="blue">Although     </font>we believe the cost of a <font color="blue">direct <font color="blue">sales force</font></font> will be comparable to that of     <font color="blue">in<font color="blue">dependent</font> agents</font>, there is also a risk that the cost may turn out to be     higher</td>
    </tr>
    <tr>
      <td>The <font color="blue">establishment</font> and <font color="blue">development</font> of a broader and more dedicated     <font color="blue">distribution</font>  network and <font color="blue">sales force</font> is expensive and time consuming</td>
    </tr>
    <tr>
      <td>Because of the <font color="blue">intense <font color="blue">competition</font></font> for their services, we may be unable to     identify <font color="blue">additional</font> qualified <font color="blue">sales <font color="blue">representatives</font></font> and in<font color="blue">dependent</font> sales     agencies</td>
    </tr>
    <tr>
      <td>Further, we may not be able to <font color="blue"><font color="blue">enter into</font> <font color="blue">agreements</font> with them on</font>     <font color="blue">commercially</font>  reasonable  terms,  if  at all</td>
    </tr>
    <tr>
      <td>Even if we do <font color="blue">enter into</font>     <font color="blue">agreements</font> with <font color="blue">additional</font> <font color="blue">sales <font color="blue">representatives</font></font> and/or in<font color="blue">dependent</font> sales     agencies, these <font color="blue">parties may</font> not be successful in marketing and selling our     products</td>
    </tr>
    <tr>
      <td>Our business, <font color="blue">financial condition</font> and results of <font color="blue">operations</font> will     be <font color="blue"><font color="blue"><font color="blue">adversely</font> affect</font>ed</font> if the marketing and <font color="blue">sales efforts</font> of our <font color="blue">direct sales</font>     <font color="blue">representatives</font> and in<font color="blue">dependent</font> sales agencies are <font color="blue">unsuccessful</font></td>
    </tr>
    <tr>
      <td>Pricing <font color="blue">pressure from</font> our <font color="blue"><font color="blue">competitor</font>s</font> and sources of <font color="blue">medical <font color="blue">reimbursement</font></font>     may impact our ability to sell our <font color="blue">products at prices <font color="blue">necessary</font></font> to expand     our <font color="blue">operations</font> and <font color="blue">reach <font color="blue">profitability</font></font></td>
    </tr>
    <tr>
      <td>The market for <font color="blue">spine surgery</font> products is large and <font color="blue">growing at</font> a     <font color="blue">significant</font>  rate</td>
    </tr>
    <tr>
      <td>This  has  attracted  numerous  new  companies and     <font color="blue">technologies</font>,  and  encouraged more <font color="blue">established companies</font> to intensify     <font color="blue"><font color="blue">competitive</font> pressure</font></td>
    </tr>
    <tr>
      <td>New entrants to our markets include companies owned     <font color="blue">partially by <font color="blue">spine surgeons</font></font>, who have <font color="blue">significant</font> market knowledge and     access to the surgeons who use our products</td>
    </tr>
    <tr>
      <td>As a result of this increased     <font color="blue">competition</font>, we believe there will be growing pricing pressure in the near     future</td>
    </tr>
    <tr>
      <td>If <font color="blue"><font color="blue">competitive</font> forces drive down</font> the price we are able to charge for     our products, our profit margins will shrink, which will hamper our ability     to invest in and grow our business</td>
    </tr>
    <tr>
      <td>Further,  successful  sales  of our <font color="blue">products will depend on</font> the     <font color="blue">availability</font> of adequate <font color="blue">reimbursement</font> from third-party payors</td>
    </tr>
    <tr>
      <td><font color="blue">Healthcare     </font>providers, such as hospitals that <font color="blue">purchase <font color="blue">medical devices</font></font> for treatment of     their patients, generally rely on third-party payors to reimburse all or     part of the costs and <font color="blue">fees associated with</font> the procedures performed with     these devices</td>
    </tr>
    <tr>
      <td>Spine surgeons are unlikely to use our products if they do     not receive <font color="blue"><font color="blue">reimbursement</font> adequate</font> to cover the cost of their <font color="blue">involvement</font> in     the <font color="blue">surgical procedures</font></td>
    </tr>
    <tr>
      <td>We also believe that <font color="blue">future <font color="blue">reimbursement</font> may</font> be     subject  to  increased  <font color="blue">restrictions</font>  both in the <font color="blue">United States </font>and in     <font color="blue"><font color="blue">international</font> markets</font></td>
    </tr>
    <tr>
      <td>Future legislation, regulation or <font color="blue">reimbursement</font>     policies of third-party payors may <font color="blue"><font color="blue">adversely</font> affect</font> the demand for our     <font color="blue">existing products</font> or our products currently under <font color="blue">development</font> and limit our     ability to sell our <font color="blue">products on</font> a <font color="blue">profitable basis</font></td>
    </tr>
    <tr>
      <td>To the extent we sell our products <font color="blue">international</font>ly, market <font color="blue">acceptance</font>     may  depend,  in  part,  upon the <font color="blue">availability</font> of <font color="blue">reimbursement</font> within     prevailing healthcare payment systems</td>
    </tr>
    <tr>
      <td><font color="blue">Reimbursement </font>and healthcare payment     systems in <font color="blue"><font color="blue">international</font> markets</font> vary <font color="blue">significant</font>ly by country, and include     both <font color="blue">government</font> sponsored healthcare and private insurance</td>
    </tr>
    <tr>
      <td>We are in a <font color="blue">highly <font color="blue">competitive</font> market</font> segment and face <font color="blue">competition</font> from     large, well-established medical device <font color="blue"><font color="blue"><font color="blue">manufacture</font>rs</font> as well as new market</font>     entrants</td>
    </tr>
    <tr>
      <td>The market for <font color="blue">spine surgery</font> products and procedures is intensely     <font color="blue">competitive</font>, subject to rapid change and <font color="blue">significant</font>ly affected by new     <font color="blue">product <font color="blue">introduction</font>s</font> and other <font color="blue">market <font color="blue">activities</font></font> of <font color="blue">industry participants</font></td>
    </tr>
    <tr>
      <td>With respect to NeuroVision, our <font color="blue">nerve avoidance system</font>, we <font color="blue">compete with</font>     Medtronic Sofamor Danek, Inc, a wholly owned subsidiary of Medtronic, Inc,     and Nicolet Biomedical, a VIASYS Healthcare company, both of which have     <font color="blue">significant</font>ly greater resources than we do</td>
    </tr>
    <tr>
      <td>With respect to MaXcess, our     <font color="blue">minimally disruptive surgical system</font>, our largest <font color="blue"><font color="blue">competitor</font>s</font> are Medtronic     Sofamor Danek, Inc, DePuy Spine, Inc, a Johnson &amp; Johnson company, and     Synthes-Stratec,  Inc</td>
    </tr>
    <tr>
      <td>We <font color="blue">compete with</font> many of the <font color="blue">same companies with</font>     respect to our other products</td>
    </tr>
    <tr>
      <td>At any time, these companies may develop     <font color="blue">alternative</font> treatments, products or procedures for the treatment of spine     disorders that <font color="blue">compete directly</font> or <font color="blue">indirectly with</font> our products</td>
    </tr>
    <tr>
      <td>Many of our     larger                                         18       _________________________________________________________________    [71]Table of <font color="blue">Contents       </font><font color="blue"><font color="blue">competitor</font>s</font> are <font color="blue">either publicly traded</font> or divisions or <font color="blue">subsidiaries</font> of     <font color="blue">publicly traded companies</font>, and enjoy several <font color="blue">competitive</font> advantages over us,     including:         •  <font color="blue">significant</font>ly greater name recognition;         •  established relations with <font color="blue">spine surgeons</font>, hospitals, other healthcare     providers and third-party payors;          •   large  and  established  <font color="blue">distribution</font> networks with <font color="blue">significant</font>     <font color="blue">international</font> presence;         •  products <font color="blue">supported by</font> long-term <font color="blue">clinical data</font>;         •  greater experience in obtaining and maintaining <font color="blue">United States </font>Food and     Drug Administration, or FDA, and other <font color="blue"><font color="blue"><font color="blue">regulatory</font> approval</font>s</font> or <font color="blue">clearances</font>     for products and <font color="blue">product <font color="blue"><font color="blue">enhancement</font>s</font></font>;         •  more <font color="blue">expansive portfolios</font> of <font color="blue"><font color="blue"><font color="blue">intellectual</font> property</font> rights</font>; and          •   greater  financial and other resources for <font color="blue">product research</font> and     <font color="blue">development</font>, sales and marketing and <font color="blue">litigation</font></td>
    </tr>
    <tr>
      <td>In addition, the <font color="blue">spine industry</font> is <font color="blue">becoming <font color="blue">increasingly</font></font> crowded with     <font color="blue">new market entrants</font>, including companies owned <font color="blue">at least partially by spine</font>     surgeons</td>
    </tr>
    <tr>
      <td>Many of these new <font color="blue"><font color="blue">competitor</font>s</font> focus on a specific product or     market segment, making it more <font color="blue">difficult</font> for us to increase our overall     market  position</td>
    </tr>
    <tr>
      <td>If these <font color="blue">companies become successful</font>, we expect that     <font color="blue">competition</font>  <font color="blue">will become even</font> more intense, leading to <font color="blue">greater pricing</font>     pressure and making it more <font color="blue">difficult</font> for us to expand</td>
    </tr>
    <tr>
      <td>To be <font color="blue">commercially</font> successful, we <font color="blue">must convince <font color="blue">spine surgeons</font></font> that our     products are an attractive <font color="blue">alternative</font> to <font color="blue">existing surgical treatments</font> of     <font color="blue">spine disorders</font></td>
    </tr>
    <tr>
      <td>We believe <font color="blue"><font color="blue">spine surgeons</font> may</font> not <font color="blue">widely adopt</font> our <font color="blue">products unless</font>     they  determine, <font color="blue">based on</font> experience, <font color="blue">clinical data</font> and published peer     reviewed  journal  articles,  that our <font color="blue">products provide benefits</font> or an     attractive  <font color="blue">alternative</font>  to  <font color="blue">conventional modalities</font> of <font color="blue">treating spine</font>     disorders</td>
    </tr>
    <tr>
      <td>Surgeons may be slow to change their <font color="blue">medical treatment practices</font>     for the following reasons, among others:         •  lack of experience with our products;         •  lack of <font color="blue">evidence supporting <font color="blue">additional</font> patient benefits</font>;         •  perceived <font color="blue">liability risks generally associated with</font> the use of new     products and procedures;          •   limited <font color="blue">availability</font> of <font color="blue">reimbursement</font> within healthcare payment     systems;         •  <font color="blue">costs associated with</font> the purchase of <font color="blue">new products</font> and equipment; and         •  the time that must be dedicated for training</td>
    </tr>
    <tr>
      <td>In addition, we believe <font color="blue">recommendations</font> and support of our <font color="blue">products by</font>     <font color="blue">influential surgeons</font> are essential for market <font color="blue">acceptance</font> and adoption</td>
    </tr>
    <tr>
      <td>If we     do not receive <font color="blue">support from such surgeons</font> or have favorable long-term data,     surgeons and <font color="blue">hospitals may</font> not use our products</td>
    </tr>
    <tr>
      <td>In such <font color="blue">circumstances</font>, we     may not achieve expected revenues and <font color="blue">may never <font color="blue">become profitable</font></font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">future success depends on</font> our ability to timely develop and introduce     <font color="blue">new products</font> or <font color="blue">product <font color="blue"><font color="blue">enhancement</font>s</font></font> that will be <font color="blue">accepted by</font> the market</td>
    </tr>
    <tr>
      <td>It is important to our business that we continue to build a more     complete <font color="blue">product offering</font> to surgeons and hospitals</td>
    </tr>
    <tr>
      <td>As such, our success     will depend in part on our ability to develop and introduce <font color="blue">new products</font> and     <font color="blue"><font color="blue">enhancement</font>s</font> to our <font color="blue">existing products</font> to keep pace with the rapidly changing     <font color="blue">spine market</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot assure</font> you that we will be able to <font color="blue">successfully</font>     develop, obtain <font color="blue"><font color="blue">regulatory</font> approval</font> for or market <font color="blue">new products</font> or that any     of our <font color="blue"><font color="blue">future products</font> will</font> be <font color="blue">accepted by</font> the surgeons who use our products     or the payors who <font color="blue">financially</font>                                         19       _________________________________________________________________    [72]Table of <font color="blue">Contents       </font>support many of the procedures performed with our products</td>
    </tr>
    <tr>
      <td>The success of     any new <font color="blue">product offering</font> or <font color="blue">enhancement</font> to an <font color="blue">existing product will depend</font>     <font color="blue">on several factors</font>, including our ability to:         •  properly identify and anticipate surgeon and patient needs;         •  develop and introduce <font color="blue">new products</font> or <font color="blue">product <font color="blue"><font color="blue">enhancement</font>s</font></font> in a timely     manner;         •  develop products <font color="blue">based on</font> <font color="blue">technology</font> that we acquire, such as the     <font color="blue"><font color="blue">technology</font> recently</font> acquired from Pearsalls Limited, RSB Spine LLC, and     RiverBend Design LLC;          •   <font color="blue">avoid infringing upon</font> the <font color="blue"><font color="blue"><font color="blue">intellectual</font> property</font> rights</font> of third     parties;         •  <font color="blue">demonstrate</font>, if required, the safety and efficacy of <font color="blue">new products</font> with     <font color="blue">data from preclinical studies</font> and <font color="blue">clinical trials</font>;          •   obtain the <font color="blue">necessary</font> <font color="blue">regulatory</font> <font color="blue">clearances</font> or approvals for new     products or <font color="blue">product <font color="blue"><font color="blue">enhancement</font>s</font></font>;         •  <font color="blue">provide <font color="blue">adequate training</font></font> to <font color="blue">potential users</font> of our products;         •  receive adequate <font color="blue">reimbursement</font>; and         •  develop an <font color="blue">effective</font> and <font color="blue">dedicated marketing</font> and <font color="blue">distribution</font> network</td>
    </tr>
    <tr>
      <td>If we do not develop <font color="blue">new products</font> or <font color="blue">product <font color="blue"><font color="blue">enhancement</font>s</font></font> in time to     <font color="blue">meet market demand</font> or if there is insufficient demand for these products or     <font color="blue"><font color="blue">enhancement</font>s</font>, our results of <font color="blue">operations</font> will suffer</td>
    </tr>
    <tr>
      <td>We may encounter <font color="blue">difficult</font>ies in <font color="blue">integrating</font> acquired products, <font color="blue">technologies</font>     or businesses, which <font color="blue">could <font color="blue"><font color="blue">adversely</font> affect</font></font> our business</td>
    </tr>
    <tr>
      <td>We recently acquired <font color="blue">assets from each</font> of Pearsalls Limited, RSB Spine     LLC, and RiverBend Design LLC, and may in the future acquire <font color="blue">technology</font>,     products or businesses related to our current or future business</td>
    </tr>
    <tr>
      <td>We have     limited  experience  in  <font color="blue"><font color="blue">acquisition</font> <font color="blue">activities</font></font> and may have to devote     substantial time and resources in order to complete any <font color="blue">future <font color="blue">acquisition</font>s</font></td>
    </tr>
    <tr>
      <td>Further, these past and potential <font color="blue">acquisition</font>s entail risks, uncertainties     and <font color="blue">potential disruptions</font> to our business</td>
    </tr>
    <tr>
      <td>For example, we may not be able     to <font color="blue">successfully</font> integrate an acquired company’s <font color="blue">operations</font>, <font color="blue">technologies</font>,     products and services, information systems and <font color="blue">personnel into</font> our business</td>
    </tr>
    <tr>
      <td>Further, products we acquire, such as the <font color="blue">cervical plate</font> we acquired from     RSB Spine LLC and the ExtenSure product acquired from RiverBend Design LLC,     may not provide the <font color="blue">intended complementary fit with</font> our <font color="blue">existing products</font></td>
    </tr>
    <tr>
      <td>In  addition,  certain acquired <font color="blue">technology</font>, such as that acquired from     Pearsalls Limited, requires <font color="blue">significant</font> <font color="blue">additional</font> <font color="blue">development</font> work and     efforts to obtain <font color="blue"><font color="blue">regulatory</font> clearance</font> or approval</td>
    </tr>
    <tr>
      <td>An <font color="blue"><font color="blue">acquisition</font> may</font>     further strain our <font color="blue">existing financial</font> and <font color="blue">managerial controls</font>, and divert     <font color="blue">management</font>’s attention away from our other business concerns</td>
    </tr>
    <tr>
      <td>In <font color="blue">connection</font>     with  in-process  research and <font color="blue">development</font> <font color="blue">activities</font>, we <font color="blue">would likely</font>     experience an increase in <font color="blue">development</font> expenses and <font color="blue">capital expenditures</font></td>
    </tr>
    <tr>
      <td>There may also be <font color="blue">unanticipated costs</font> and <font color="blue">liabilities associated with</font> an     <font color="blue">acquisition</font> that <font color="blue">could <font color="blue"><font color="blue">adversely</font> affect</font></font> our operating results</td>
    </tr>
    <tr>
      <td>We are <font color="blue">dependent</font> on single source suppliers and <font color="blue"><font color="blue">manufacture</font>rs</font> for certain of     our products and <font color="blue">components</font>, and the loss of any of these suppliers or     <font color="blue"><font color="blue">manufacture</font>rs</font>, or their <font color="blue">inability</font> to <font color="blue">supply us with</font> an <font color="blue">adequate supply</font> of     <font color="blue">materials could harm</font> our business</td>
    </tr>
    <tr>
      <td>We rely on third-party suppliers and <font color="blue"><font color="blue">manufacture</font>rs</font> to <font color="blue">manufacture</font> and     supply our products</td>
    </tr>
    <tr>
      <td>To be successful, our contract <font color="blue"><font color="blue">manufacture</font>rs</font> must be     able to <font color="blue">provide us with products</font> and <font color="blue">components</font> in substantial quantities,     in <font color="blue"><font color="blue">compliance with</font> <font color="blue">regulatory</font> <font color="blue">requirement</font>s</font>, in <font color="blue">accordance with agreed upon</font>     specifications, at acceptable cost and on a <font color="blue">timely basis</font></td>
    </tr>
    <tr>
      <td>Our anticipated     <font color="blue">growth could</font> strain the ability of suppliers to deliver an <font color="blue">increasingly</font>     large supply of products, materials and <font color="blue">components</font></td>
    </tr>
    <tr>
      <td><font color="blue">Manufacturers </font>often     experience <font color="blue">difficult</font>ies in <font color="blue">scaling up production</font>, including <font color="blue">problems with</font>     production  yields  and <font color="blue">quality control</font> and assurance, especially with     <font color="blue">products such as allograft which</font> is <font color="blue">processed human tissue</font></td>
    </tr>
    <tr>
      <td>If we are unable     to obtain <font color="blue">sufficient quantities</font> of high quality <font color="blue">components</font> to <font color="blue">meet customer</font>     <font color="blue">demand on</font> a <font color="blue">timely basis</font>, we <font color="blue">could lose customers</font>, our <font color="blue">reputation may</font> be     harmed and our business <font color="blue">could suffer</font></td>
    </tr>
    <tr>
      <td>20       _________________________________________________________________    [73]Table of <font color="blue">Contents       </font>      We <font color="blue">currently use one</font> or two <font color="blue"><font color="blue">manufacture</font>rs</font> for each of our devices or     <font color="blue">components</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">dependence on one</font> or two <font color="blue"><font color="blue">manufacture</font>rs</font> involves several     risks, including limited control over pricing, <font color="blue">availability</font>, quality and     <font color="blue">delivery schedules</font></td>
    </tr>
    <tr>
      <td>If any one or more of our <font color="blue"><font color="blue">manufacture</font>rs</font> cease to provide     us with <font color="blue">sufficient quantities</font> of our <font color="blue">components</font> in a <font color="blue">timely manner</font> or on     terms acceptable to us, or cease to <font color="blue">manufacture</font> <font color="blue">components</font> of acceptable     quality, we would have to seek <font color="blue">alternative</font> sources of <font color="blue">manufacturing</font></td>
    </tr>
    <tr>
      <td>We     could  incur  delays  while we locate and engage <font color="blue">alternative</font> qualified     suppliers  and  we  might be unable to engage <font color="blue">alternative</font> suppliers on     favorable terms</td>
    </tr>
    <tr>
      <td>Any <font color="blue">such disruption</font> or <font color="blue">increased expenses could harm</font> our     <font color="blue"><font color="blue">commercialization</font> efforts</font> and <font color="blue"><font color="blue">adversely</font> affect</font> our ability to generate     revenue</td>
    </tr>
    <tr>
      <td>Further, Tissue Banks International, Inc</td>
    </tr>
    <tr>
      <td>and <font color="blue">US Tissue and Cell     </font>(formerly Intermountain Tissue Center) collectively <font color="blue">supply us with</font> all of     our <font color="blue"><font color="blue">allograft implant</font>s</font>, and <font color="blue">will continue</font> to be our <font color="blue">only sources</font> for the     <font color="blue">foreseeable future</font></td>
    </tr>
    <tr>
      <td>The processing of human tissue into <font color="blue"><font color="blue">allograft implant</font>s</font>     is very <font color="blue">labor intensive</font> and it is therefore <font color="blue">difficult</font> to maintain a steady     <font color="blue">supply stream</font></td>
    </tr>
    <tr>
      <td>In addition, due to seasonal changes in <font color="blue">mortality rates</font>, some     <font color="blue">scarce tissues used</font> for our <font color="blue"><font color="blue">allograft implant</font>s</font> are at times in <font color="blue">particularly</font>     short supply</td>
    </tr>
    <tr>
      <td>We cannot be certain that our supply of <font color="blue"><font color="blue">allograft implant</font>s</font>     from Tissue Banks International and US Tissue and Cell will be available     <font color="blue">at current levels</font> or will be sufficient to meet our needs</td>
    </tr>
    <tr>
      <td>If we are no     <font color="blue">longer able</font> to obtain <font color="blue"><font color="blue">allograft implant</font>s</font> from these sources in amounts     sufficient  to meet our needs, we may not be able to locate and engage     <font color="blue"><font color="blue">replacement</font> sources</font> of <font color="blue"><font color="blue">allograft implant</font>s</font> on <font color="blue">commercially</font> reasonable terms,     if at all</td>
    </tr>
    <tr>
      <td>Any <font color="blue">interruption</font> of our business caused by the need to locate     <font color="blue">additional</font>  sources of <font color="blue"><font color="blue">allograft implant</font>s</font> could <font color="blue">significant</font>ly harm our     revenues, <font color="blue">which could</font> cause the <font color="blue">market price</font> of our <font color="blue">common stock</font> to decline</td>
    </tr>
    <tr>
      <td>is  our  exclusive  supplier  of     <font color="blue">polyetheretherketone</font>,  <font color="blue">which comprises</font> our PEEK <font color="blue">partial vertebral</font> body     <font color="blue">product called</font> CoRoent</td>
    </tr>
    <tr>
      <td>We have a <font color="blue">supply agreement with</font> Invibio, pursuant to     which we have agreed to purchase our <font color="blue">entire supply</font> of <font color="blue">polyetheretherketone</font>     from Invibio</td>
    </tr>
    <tr>
      <td>In addition, we have an exclusive supply arrangement with Peak     Industries,  Inc,  pursuant to which <font color="blue">Peak Industries </font>is our exclusive     supplier of <font color="blue">NeuroVision </font>systems</td>
    </tr>
    <tr>
      <td>In the event <font color="blue">Peak Industries </font>ceases to     supply us, which it may do at any time, we would be forced to locate a     suitable <font color="blue">alternative</font> supplier</td>
    </tr>
    <tr>
      <td>We believe the start-up time to establish a     new supply of <font color="blue">NeuroVision </font>would be <font color="blue">approximately</font> 16 to 20 weeks</td>
    </tr>
    <tr>
      <td>We have     established  an inventory of <font color="blue">NeuroVision </font>systems to <font color="blue">help us bridge</font> any     downtime in the event <font color="blue">Peak Industries </font>ceases to supply us; however, this     inventory  may  be  depleted before we are able to engage an alternate     supplier</td>
    </tr>
    <tr>
      <td>Any <font color="blue">inability</font> to meet our customers’ demands for <font color="blue">NeuroVision </font>    <font color="blue">systems could lead</font> to <font color="blue">decreased sales</font> and harm our reputation, <font color="blue">which could</font>     cause the <font color="blue">market price</font> of our <font color="blue">common stock</font> to decline</td>
    </tr>
    <tr>
      <td>Any failure in our efforts to train <font color="blue">spine surgeons</font> could <font color="blue">significant</font>ly     reduce the market <font color="blue">acceptance</font> of our products</td>
    </tr>
    <tr>
      <td>There is a <font color="blue">learning process involved</font> for <font color="blue">spine surgeons</font> to become     proficient in the use of our products</td>
    </tr>
    <tr>
      <td>It is critical to the success of our     <font color="blue"><font color="blue">commercialization</font> efforts</font> to train a sufficient number of <font color="blue">spine surgeons</font> and     to <font color="blue">provide them with adequate instruction</font> in the use of our products</td>
    </tr>
    <tr>
      <td><font color="blue">This     </font><font color="blue">training process may</font> take <font color="blue">longer than</font> expected and <font color="blue">may therefore affect</font> our     ability to <font color="blue">increase sales</font></td>
    </tr>
    <tr>
      <td><font color="blue">Convincing </font>surgeons to dedicate the time and     <font color="blue">energy <font color="blue">necessary</font></font> for <font color="blue">adequate training</font> is <font color="blue">challenging</font>, and we <font color="blue">cannot assure</font>     you we will be successful in these efforts</td>
    </tr>
    <tr>
      <td>If surgeons are not properly     trained, they may misuse or in<font color="blue">effective</font>ly use our products</td>
    </tr>
    <tr>
      <td>This may also     result  in  unsatisfactory  patient outcomes, patient injury, negative     publicity or <font color="blue">lawsuits <font color="blue">against us</font></font>, any of <font color="blue">which could</font> have an adverse effect     on our business</td>
    </tr>
    <tr>
      <td>Although we believe our training methods regarding surgeons are     conducted in <font color="blue">compliance with</font> FDA and other <font color="blue">applicable <font color="blue">regulations</font></font>, if the     FDA determines that our <font color="blue">training constitutes promotion</font> of an <font color="blue">unapproved use</font>,     they <font color="blue">could request</font> that we modify our training or subject us to <font color="blue">regulatory</font>     <font color="blue"><font color="blue">enforcement</font> actions</font>, including the issuance of a warning letter, injunction,     seizure, civil fine and <font color="blue">criminal penalty</font></td>
    </tr>
    <tr>
      <td>We are <font color="blue">dependent</font> on the services of <font color="blue">Alexis V Lukianov </font>and Keith Valentine,     and the loss of either of <font color="blue">them could harm</font> our business</td>
    </tr>
    <tr>
      <td>Our <font color="blue">continued success depends</font> in part upon the <font color="blue">continued service</font> of     Alexis V Lukianov, our Chairman and Chief Executive Officer, and Keith     Valentine, our President, who are critical to the <font color="blue">overall <font color="blue">management</font></font>                                         21       _________________________________________________________________    [74]Table of <font color="blue">Contents       </font>of NuVasive as well as to the <font color="blue">development</font> of our <font color="blue">technology</font>, our culture and     our <font color="blue">strategic direction</font></td>
    </tr>
    <tr>
      <td>We have <font color="blue">entered into employment <font color="blue">agreements</font> with</font>     Messrs</td>
    </tr>
    <tr>
      <td>Lukianov and Valentine, but neither of these <font color="blue"><font color="blue">agreements</font> guarantees</font>     the service of the individual for a <font color="blue">specified period</font> of time</td>
    </tr>
    <tr>
      <td>Lukianov or Valentine could have a material adverse effect on     our business, results of <font color="blue">operations</font> and <font color="blue">financial condition</font></td>
    </tr>
    <tr>
      <td>If we fail to <font color="blue">properly manage</font> our anticipated growth, our business could     suffer</td>
    </tr>
    <tr>
      <td>The <font color="blue">rapid growth</font> of our business has placed a <font color="blue">significant</font> strain on     our managerial, operational and <font color="blue">financial resources</font> and systems</td>
    </tr>
    <tr>
      <td>To execute     our anticipated growth <font color="blue">successfully</font>, we <font color="blue">must attract</font> and retain qualified     personnel and manage and train them <font color="blue">effective</font>ly</td>
    </tr>
    <tr>
      <td>We will be <font color="blue">dependent</font> on our     personnel  and  <font color="blue">third parties</font> to <font color="blue">effective</font>ly market our products to an     increasing number of surgeons</td>
    </tr>
    <tr>
      <td>We <font color="blue">will also depend on</font> our personnel to     develop next generation <font color="blue">technologies</font></td>
    </tr>
    <tr>
      <td>Further, our anticipated <font color="blue">growth will</font> place <font color="blue">additional</font> strain on our     suppliers and <font color="blue"><font color="blue">manufacture</font>rs</font>, resulting in increased need for us to <font color="blue">carefully</font>     monitor  quality  assurance</td>
    </tr>
    <tr>
      <td>Any  failure  by us to manage our growth     <font color="blue">effective</font>ly could have an adverse effect on our ability to achieve our     <font color="blue">development</font> and <font color="blue"><font color="blue">commercialization</font> goals</font></td>
    </tr>
    <tr>
      <td><font color="blue">In January </font>2005, we relocated our <font color="blue">operations</font> to a <font color="blue">different <font color="blue">facility</font></font>     in San Diego, California</td>
    </tr>
    <tr>
      <td>Although this <font color="blue">new <font color="blue">facility</font> allows</font> for growth in     our business and <font color="blue">enables us</font> to more <font color="blue">effective</font>ly train surgeons in the use of     our products, it has <font color="blue">significant</font>ly increased our operating expenses</td>
    </tr>
    <tr>
      <td>For     example, our <font color="blue">monthly lease payments <font color="blue">approximately</font> doubled</font> and we also pay     increased  maintenance  costs for this <font color="blue">facility</font></td>
    </tr>
    <tr>
      <td>If we do not generate     <font color="blue">additional</font>  business  <font color="blue">opportunities</font>,  these  <font color="blue">additional</font> expenses could     <font color="blue">negatively</font> affect our results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>If we fail to obtain, or experience <font color="blue">significant</font> delays in obtaining, FDA     <font color="blue">clearances</font> or approvals for our <font color="blue">future products</font> or <font color="blue">product <font color="blue"><font color="blue">enhancement</font>s</font></font>, our     ability to <font color="blue">commercially</font> distribute and market our products <font color="blue">could suffer</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">medical devices</font> are subject to <font color="blue"><font color="blue">rigorous regulation</font> by</font> the FDA and     numerous other federal, state and foreign <font color="blue">government</font>al <font color="blue">authorities</font></td>
    </tr>
    <tr>
      <td>The     process of obtaining <font color="blue">regulatory</font> <font color="blue">clearances</font> or approvals to market a medical     device, <font color="blue">particularly</font> from the FDA, can be costly and time consuming, and     there can be no assurance that such <font color="blue">clearances</font> or <font color="blue">approvals will</font> be granted     on a <font color="blue">timely basis</font>, if at all</td>
    </tr>
    <tr>
      <td>In particular, the FDA <font color="blue">permits commercial</font>     <font color="blue">distribution</font> of a new medical device only after the device has received     <font color="blue">clearance under</font> Section 510(k) of the Federal Food, Drug and Cosmetic Act,     or is the subject of an <font color="blue">approved <font color="blue">premarket approval</font> <font color="blue">application</font></font>, or PMA The     FDA <font color="blue">will clear marketing</font> of a medical device through the 510(k) process if     it is <font color="blue">demonstrate</font>d that the new product is <font color="blue">substantially equivalent</font> to other     510(k)-cleared  products</td>
    </tr>
    <tr>
      <td>The PMA process is more costly, lengthy and     <font color="blue">uncertain than</font> the 510(k) clearance process</td>
    </tr>
    <tr>
      <td>A PMA <font color="blue"><font color="blue">application</font> must</font> be     <font color="blue">supported by</font> extensive data, including, but not limited to, technical,     preclinical, clinical trial, <font color="blue">manufacturing</font> and <font color="blue">labeling data</font>, to <font color="blue">demonstrate</font>     to the FDA’s <font color="blue">satisfaction</font> the safety and efficacy of the device for its     <font color="blue">intended use</font></td>
    </tr>
    <tr>
      <td>Our  failure  to <font color="blue"><font color="blue">comply with</font> such <font color="blue">regulations</font> could lead</font> to the     imposition of injunctions, suspensions or loss of <font color="blue"><font color="blue"><font color="blue">regulatory</font> approval</font>s</font>,     product recalls, termination of <font color="blue">distribution</font>, or <font color="blue">product seizures</font></td>
    </tr>
    <tr>
      <td>In the     most <font color="blue">egregious</font> cases, criminal sanctions or closure of our <font color="blue">manufacturing</font>     <font color="blue">facilities</font> are possible</td>
    </tr>
    <tr>
      <td>To date, all of our products, unless exempt, have <font color="blue">been cleared through</font>     the 510(k) process</td>
    </tr>
    <tr>
      <td>We have no experience in obtaining <font color="blue">premarket approval</font></td>
    </tr>
    <tr>
      <td>We  expect  that  our  total  <font color="blue">disc <font color="blue">replacement</font></font> devices currently under     <font color="blue">development</font>, including CerPass, our <font color="blue"><font color="blue">investigation</font>al cervical total disc</font>     <font color="blue">replacement</font> device, and NeoDisc, our <font color="blue">investigation</font>al nucleus-like cervical     <font color="blue">disc <font color="blue">replacement</font></font> device, will have to go through the PMA process</td>
    </tr>
    <tr>
      <td><font color="blue">These     </font>devices have not yet reached the <font color="blue">clinical trial stage</font> and we <font color="blue">cannot assure</font>     you whether successful <font color="blue">clinical trials</font> will be conducted or completed or     <font color="blue"><font color="blue">regulatory</font> approval</font> will ultimately be obtained for these devices</td>
    </tr>
    <tr>
      <td>Moreover,     <font color="blue">clinical trials</font> typically have durations of <font color="blue">several years</font> and competing     <font color="blue">products may</font> be <font color="blue">introduced while</font> our devices are undergoing <font color="blue">clinical trials</font></td>
    </tr>
    <tr>
      <td>This <font color="blue">could reduce</font> the <font color="blue">potential demand</font> for our products and <font color="blue">negatively</font>                                         22       _________________________________________________________________    [75]Table of <font color="blue">Contents       </font>impact  our  business  prospects</td>
    </tr>
    <tr>
      <td>Our  <font color="blue"><font color="blue">competitor</font>s</font>’  <font color="blue">new products</font> and     <font color="blue">technologies</font> may be more <font color="blue">effective</font> or <font color="blue">less expensive than</font> our products or     render our <font color="blue">products obsolete</font></td>
    </tr>
    <tr>
      <td>Further, pursuant to FDA <font color="blue">regulations</font>, we can only market our products     for  cleared  or <font color="blue">approved uses</font></td>
    </tr>
    <tr>
      <td>Certain of our <font color="blue">products may</font> be used by     physicians for <font color="blue">indications</font> other than those cleared or approved by the FDA,     but we <font color="blue">cannot promote</font> the products for such off-label uses</td>
    </tr>
    <tr>
      <td>If <font color="blue">the FDA     </font>determines that our <font color="blue">promotional materials</font> or <font color="blue">training constitutes promotion</font>     of  an <font color="blue">unapproved use</font>, it <font color="blue">could request</font> that we modify our training or     <font color="blue">promotional materials</font> or subject us to <font color="blue">regulatory</font> <font color="blue"><font color="blue">enforcement</font> actions</font>,     including the issuance of a warning letter, injunction, seizure, civil fine     and <font color="blue">criminal penalties</font></td>
    </tr>
    <tr>
      <td>It is <font color="blue">also possible</font> that other federal, state or     foreign  <font color="blue">enforcement</font>  <font color="blue">authorities</font>  might  take action if they consider     promotional or <font color="blue">training materials</font> to <font color="blue">constitute promotion</font> of an unapproved     use,  <font color="blue">which could</font> result in <font color="blue">significant</font> fines or <font color="blue">penalties under</font> other     statutory <font color="blue">authorities</font></td>
    </tr>
    <tr>
      <td>Foreign <font color="blue">government</font>al <font color="blue">authorities</font> that regulate the <font color="blue">manufacture</font> and     sale of <font color="blue">medical devices</font> have become <font color="blue">increasingly</font> stringent and, to the     extent we market and sell our products in <font color="blue">foreign countries</font>, we may be     subject to <font color="blue">rigorous regulation</font> in the future</td>
    </tr>
    <tr>
      <td>In such <font color="blue">circumstances</font>, we     would rely <font color="blue">significant</font>ly on our foreign in<font color="blue">dependent</font> sales agencies to comply     with the varying <font color="blue">regulations</font>, and any <font color="blue">failures on</font> their part could result in     <font color="blue">restrictions</font> on the sale of our products in <font color="blue">foreign countries</font></td>
    </tr>
    <tr>
      <td>The safety of our products is not yet <font color="blue">supported by</font> long-term <font color="blue">clinical data</font>     and <font color="blue">may therefore prove</font> to be less safe and <font color="blue">effective</font> than initially     thought</td>
    </tr>
    <tr>
      <td>We obtained clearance to offer almost all of our products that require     FDA clearance or <font color="blue">approval through</font> the FDA’s 510(k) clearance process</td>
    </tr>
    <tr>
      <td>The     FDA’s 510(k) clearance process is <font color="blue">less rigorous than</font> the PMA process and     requires less supporting <font color="blue">clinical data</font></td>
    </tr>
    <tr>
      <td>As a result, we currently lack the     breadth of published long-term <font color="blue">clinical data</font> supporting the safety of our     products and the benefits they offer that might have <font color="blue">been generated</font> in     <font color="blue">connection</font> with the PMA process</td>
    </tr>
    <tr>
      <td>For these reasons, <font color="blue"><font color="blue">spine surgeons</font> may</font> be     slow  to adopt our products, we may not have <font color="blue">comparative data</font> that our     <font color="blue"><font color="blue">competitor</font>s</font>  have  or  are <font color="blue">generating</font> and we may be subject to greater     <font color="blue">regulatory</font> and <font color="blue"><font color="blue">product liability</font> risks</font></td>
    </tr>
    <tr>
      <td>Further, <font color="blue">future patient studies</font> or     clinical experience may indicate that <font color="blue">treatment with</font> our products does not     <font color="blue">improve patient outcomes</font></td>
    </tr>
    <tr>
      <td>Such results <font color="blue">would reduce demand</font> for our products,     <font color="blue">significant</font>ly reduce our ability to achieve expected revenues and could     prevent  us  <font color="blue">from becoming profitable</font></td>
    </tr>
    <tr>
      <td>Moreover, if future results and     experience  indicate  that  our  products  cause unexpected or serious     <font color="blue">complications</font> or other <font color="blue">unforeseen negative effects</font>, we could be subject to     <font color="blue">significant</font> legal liability and harm to our business reputation</td>
    </tr>
    <tr>
      <td>The spine     medical  device  market  has been <font color="blue">particularly</font> prone to <font color="blue">costly product</font>     liability <font color="blue">litigation</font></td>
    </tr>
    <tr>
      <td>If we or our <font color="blue">suppliers fail</font> to <font color="blue">comply with</font> the FDA’s <font color="blue">quality system</font>     <font color="blue">regulations</font>, the <font color="blue">manufacture</font> of our <font color="blue">products could</font> be delayed</td>
    </tr>
    <tr>
      <td>We and our suppliers are required to <font color="blue">comply with</font> the FDA’s quality     system <font color="blue">regulations</font>, which cover the methods and <font color="blue">documentation</font> of the design,     testing,  production, control, quality assurance, labeling, packaging,     storage and shipping of our products</td>
    </tr>
    <tr>
      <td>The FDA enforces the <font color="blue">quality system</font>     <font color="blue">regulation through <font color="blue">inspections</font></font></td>
    </tr>
    <tr>
      <td>If we or one of our <font color="blue">suppliers fail</font> a quality     system  <font color="blue">regulations</font> inspection or if any <font color="blue">corrective action</font> plan is not     sufficient, the <font color="blue">manufacture</font> of our <font color="blue">products could</font> be delayed</td>
    </tr>
    <tr>
      <td>We underwent     an FDA inspection in August 2003 regarding our <font color="blue">allograft implant</font> business,     and  another FDA inspection in April 2004 regarding our medical device     <font color="blue">activities</font></td>
    </tr>
    <tr>
      <td>In <font color="blue">connection</font> with these <font color="blue">inspections</font>, the FDA <font color="blue">requested minor</font>     <font color="blue">corrective action</font>s, which we believe we have taken, but there can be no     assurance the FDA will not subject us to further <font color="blue">enforcement</font> action</td>
    </tr>
    <tr>
      <td><font color="blue">The FDA     </font>may impose <font color="blue">additional</font> <font color="blue">inspections</font> or <font color="blue">audits at</font> any time</td>
    </tr>
    <tr>
      <td><font color="blue">Modifications </font>to our marketed <font color="blue">products may</font> require new 510(k) <font color="blue">clearances</font> or     <font color="blue">premarket approval</font>s, or may require us to <font color="blue">cease marketing</font> or recall the     modified products until <font color="blue">clearances</font> are obtained</td>
    </tr>
    <tr>
      <td>Any <font color="blue">modification</font> to a 510(k)-cleared device that could <font color="blue">significant</font>ly     affect its safety or efficacy, or that <font color="blue">would constitute</font> a major change in     its <font color="blue">intended use</font>, requires a new 510(k) clearance or, possibly, premarket     approval</td>
    </tr>
    <tr>
      <td>The FDA requires every <font color="blue">manufacture</font>r to make this <font color="blue">determination</font> in     the first instance, but <font color="blue">the FDA     </font>                                    23       _________________________________________________________________    [76]Table of <font color="blue">Contents       </font>may review any <font color="blue">manufacture</font>r’s decision</td>
    </tr>
    <tr>
      <td>The FDA may not <font color="blue">agree with</font> any of     our <font color="blue">decisions</font> regarding whether new <font color="blue">clearances</font> or approvals are <font color="blue">necessary</font></td>
    </tr>
    <tr>
      <td><font color="blue">If the FDA </font>requires us to seek 510(k) clearance or <font color="blue">premarket approval</font> for     any <font color="blue">modification</font> to a <font color="blue"><font color="blue">previously</font> cleared product</font>, we may be required to     <font color="blue">cease marketing</font> or to recall the <font color="blue">modified product until</font> we obtain clearance     or  approval, and we may be subject to <font color="blue">significant</font> <font color="blue">regulatory</font> fines or     penalties</td>
    </tr>
    <tr>
      <td>Further, our <font color="blue">products could</font> be subject to recall if <font color="blue">the FDA     </font>determines, for any reason, that our products are not safe or <font color="blue">effective</font></td>
    </tr>
    <tr>
      <td>Any     recall or FDA <font color="blue">requirement</font> that we seek <font color="blue">additional</font> approvals or <font color="blue">clearances</font>     could result in delays, fines, <font color="blue">costs associated with</font> <font color="blue">modification</font> of a     product, loss of revenue and potential operating <font color="blue">restrictions</font> imposed by the     FDA       Risks Related to Our Financial Results and Need for Financing       We have a limited operating history, have incurred <font color="blue">significant</font> operating     <font color="blue">losses since inception</font> and expect to continue to <font color="blue">incur losses</font>, and we cannot     assure you that we will achieve <font color="blue">profitability</font></td>
    </tr>
    <tr>
      <td>We were incorporated in <font color="blue">Delaware </font>in 1997, and have since focused     primarily on research and <font color="blue">development</font> and on seeking <font color="blue">regulatory</font> <font color="blue">clearances</font>     to market our products</td>
    </tr>
    <tr>
      <td>We <font color="blue">began commercial sales</font> in 2001 and have several     <font color="blue">product offering</font>s in both MAS and classic fusion</td>
    </tr>
    <tr>
      <td>We have yet to <font color="blue">demonstrate</font>     that we can <font color="blue">generate sufficient sales</font> of our products to <font color="blue">become profitable</font></td>
    </tr>
    <tr>
      <td>The extent of our future operating losses and the timing of <font color="blue">profitability</font>     are  highly  uncertain,  and  we  may  never achieve <font color="blue">profitability</font></td>
    </tr>
    <tr>
      <td>At     December 31,  2005,  we  had  an  <font color="blue">accumulated deficit</font> of <font color="blue">approximately</font>     dlra108dtta8 million</td>
    </tr>
    <tr>
      <td>It is possible that we <font color="blue">will never generate sufficient</font>     <font color="blue">revenues from</font> <font color="blue">product sales</font> to achieve <font color="blue">profitability</font></td>
    </tr>
    <tr>
      <td>Even if we do achieve     <font color="blue">significant</font>  <font color="blue">revenues from</font> our <font color="blue">product sales</font>, we expect that increased     operating expenses will result in <font color="blue">significant</font> operating losses in the near     term as we, among other things:         •  pay the <font color="blue">acquisition</font> costs (ie, purchase price and related expenses)     and continued <font color="blue">development</font> and <font color="blue">regulatory</font> costs related to our recent     <font color="blue">acquisition</font> of assets and <font color="blue">technology</font> from each of RSB Spine LLC and     Pearsalls Limited, <font color="blue">especially with respect</font> to the <font color="blue">significant</font> ongoing     <font color="blue">development</font> and <font color="blue">regulatory</font> expenses associated with the assets acquired from     Pearsalls Limited;         •  grow our internal and third-party sales and <font color="blue">marketing forces</font> to expand     the <font color="blue">penetration</font> of our products in the United States, and expend <font color="blue">significant</font>     sums in <font color="blue">connection</font> with our efforts to convince <font color="blue">in<font color="blue">dependent</font> agents</font> and sales     <font color="blue">representatives</font> to <font color="blue"><font color="blue">exclusively</font> sell</font> our <font color="blue">spine surgery</font> products;         •  increase our research and <font color="blue">development</font> efforts to improve upon our     <font color="blue">existing products</font> and develop new product <font color="blue">candidates</font>, such as the potential     products resulting from the assets acquired from Pearsalls Limited; and         •  perform <font color="blue">clinical research</font> and trials on our <font color="blue">existing products</font> and     product <font color="blue">candidates</font></td>
    </tr>
    <tr>
      <td>As a result of these <font color="blue">activities</font>, we <font color="blue">may never <font color="blue">become profitable</font></font></td>
    </tr>
    <tr>
      <td><font color="blue">Even     </font>if we do achieve <font color="blue">profitability</font>, we may not be able to sustain or increase     <font color="blue">profitability</font> on an <font color="blue">ongoing basis</font></td>
    </tr>
    <tr>
      <td>In addition, our in<font color="blue">dependent</font> distributors     are entitled to <font color="blue">certain payments</font> in the event their services are terminated     in  <font color="blue">connection</font>  with (or <font color="blue">shortly following</font>) a change of control of our     company</td>
    </tr>
    <tr>
      <td>These payments are the <font color="blue">responsibility</font> of our successor, but may     represent an <font color="blue">additional</font> <font color="blue">significant</font> expense or reduce the price paid in     <font color="blue">connection</font> with any such event</td>
    </tr>
    <tr>
      <td>Our <font color="blue">quarterly financial</font> results are likely to fluctuate <font color="blue">significant</font>ly     because our <font color="blue">sales prospects</font> are uncertain</td>
    </tr>
    <tr>
      <td>Our quarterly operating results are <font color="blue">difficult</font> to predict and may     fluctuate <font color="blue">significant</font>ly from period to period, <font color="blue">particularly</font> because our     <font color="blue">sales prospects</font> are uncertain</td>
    </tr>
    <tr>
      <td>These <font color="blue">fluctuations will also affect</font> our     annual  operating  results  and  may  cause those results to fluctuate     <font color="blue">unexpectedly from year</font> to year</td>
    </tr>
    <tr>
      <td>The level of our revenues and results of     <font color="blue">operations</font>  at any given time will be <font color="blue">based primarily on</font> the following     factors:         •  our ability to <font color="blue">drive increased sales</font> of our products to hospitals and     surgeons;         •  our ability to establish and maintain an <font color="blue">effective</font> and <font color="blue">dedicated sales</font>     force;          •   pricing  <font color="blue">pressure applicable</font> to our products, including adverse     third-party <font color="blue">reimbursement</font> outcomes;                                         24       _________________________________________________________________    [77]Table of <font color="blue">Contents       </font>  •  results of <font color="blue">clinical research</font> and trials on our <font color="blue">existing products</font> and     products in <font color="blue">development</font> and our ability to obtain FDA approval or clearance;         •  the mix of our products sold (ie, profit margins differ between our     products);          •  timing of new <font color="blue">product offering</font>s, <font color="blue">acquisition</font>s, licenses or other     <font color="blue">significant</font> events by us or our <font color="blue"><font color="blue">competitor</font>s</font>;         •  the ability of our suppliers to <font color="blue">timely provide us with</font> an adequate     supply of materials and <font color="blue">components</font>;         •  the evolving <font color="blue">product offering</font>s of our <font color="blue"><font color="blue">competitor</font>s</font> and the potential     <font color="blue">introduction</font> of new and competing <font color="blue">technologies</font>;         •  <font color="blue"><font color="blue"><font color="blue">regulatory</font> approval</font>s</font> and <font color="blue">legislative</font> changes <font color="blue">affecting</font> the products we     may offer or those of our <font color="blue"><font color="blue">competitor</font>s</font>; and         •  <font color="blue">interruption</font> in the <font color="blue">manufacturing</font> or <font color="blue">distribution</font> of our products</td>
    </tr>
    <tr>
      <td>Many of the products we may seek to develop and introduce in the     <font color="blue">future will</font> require FDA approval or clearance, without which we <font color="blue">cannot begin</font>     to <font color="blue"><font color="blue">commercialize</font> them</font> in the United States, and <font color="blue">commercialization</font> of them     outside of the <font color="blue">United States </font><font color="blue">would likely</font> require other <font color="blue"><font color="blue"><font color="blue">regulatory</font> approval</font>s</font>     and <font color="blue">import licenses</font></td>
    </tr>
    <tr>
      <td>As a result, it will be <font color="blue">difficult</font> for us to forecast     demand for these products with any degree of <font color="blue">certainty</font></td>
    </tr>
    <tr>
      <td>In addition, we will     be  increasing  our  operating  expenses  as  we  build our commercial     <font color="blue">capabilities</font></td>
    </tr>
    <tr>
      <td>Accordingly, we may experience <font color="blue">significant</font>, unanticipated     <font color="blue">quarterly losses</font></td>
    </tr>
    <tr>
      <td>Because of these factors, our operating results in one or     more  future  quarters may fail to meet the <font color="blue">expectations</font> of securities     analysts or investors</td>
    </tr>
    <tr>
      <td>Risks Related to Our Intellectual Property and Potential <font color="blue">Litigation </font>      Our ability to protect our <font color="blue"><font color="blue">intellectual</font> property</font> and <font color="blue">proprietary</font> <font color="blue">technology</font>     <font color="blue">through patents</font> and other means is uncertain</td>
    </tr>
    <tr>
      <td>Our success depends <font color="blue">significant</font>ly on our ability to protect our     <font color="blue"><font color="blue">proprietary</font> rights</font> to the <font color="blue">technologies</font> used in our products</td>
    </tr>
    <tr>
      <td>We rely on     patent protection, as well as a <font color="blue">combination</font> of copyright, trade secret and     <font color="blue">trademark laws</font>, and non<font color="blue">disclosure</font>, confidentiality and other <font color="blue">contractual</font>     <font color="blue">restrictions</font> to protect our <font color="blue">proprietary</font> <font color="blue">technology</font></td>
    </tr>
    <tr>
      <td>However, these legal     means <font color="blue">afford only</font> limited protection and may not <font color="blue">adequately protect</font> our     rights or <font color="blue">permit us</font> to gain or keep any <font color="blue">competitive</font> advantage</td>
    </tr>
    <tr>
      <td>For example,     our pending US and foreign patent <font color="blue"><font color="blue">application</font>s</font> may not issue as patents in     a form that will be <font color="blue">advantageous</font> to us or may issue and be <font color="blue">subsequently</font>     <font color="blue">successfully</font> challenged by others and invalidated</td>
    </tr>
    <tr>
      <td>In addition, our pending     patent <font color="blue"><font color="blue">application</font>s</font> include claims to material aspects of our products and     procedures that are not <font color="blue">currently protected by issued patents</font></td>
    </tr>
    <tr>
      <td>Both the     patent <font color="blue">application</font> process and the process of <font color="blue">managing patent disputes</font> can     be time consuming and expensive</td>
    </tr>
    <tr>
      <td><font color="blue">Competitors </font>may be able to <font color="blue">design around</font>     our patents or develop <font color="blue">products which provide outcomes which</font> are comparable     to ours</td>
    </tr>
    <tr>
      <td>Although we have taken steps to protect our <font color="blue"><font color="blue">intellectual</font> property</font>     and  <font color="blue">proprietary</font>  <font color="blue">technology</font>,  including <font color="blue">entering into confidentiality</font>     <font color="blue">agreements</font>  and  <font color="blue">intellectual</font>  property assignment <font color="blue">agreements</font> with our     officers, employees, consultants and advisors, such <font color="blue">agreements</font> may not be     enforceable or may not <font color="blue">provide meaningful protection</font> for our <font color="blue">trade secrets</font>     or  other  <font color="blue">proprietary</font> information in the event of <font color="blue">unauthorized use</font> or     <font color="blue">disclosure</font> or other breaches of the <font color="blue">agreements</font></td>
    </tr>
    <tr>
      <td>Furthermore, the laws of     some <font color="blue">foreign countries</font> may not protect our <font color="blue"><font color="blue"><font color="blue">intellectual</font> property</font> rights</font> to     the same extent as do the laws <font color="blue">of the United States</font></td>
    </tr>
    <tr>
      <td>In  the  event  a <font color="blue">competitor</font> infringes upon our patent or other     <font color="blue">intellectual</font>  property  rights,  enforcing those <font color="blue">rights may</font> be costly,     <font color="blue">difficult</font> and time consuming</td>
    </tr>
    <tr>
      <td>Even if successful, <font color="blue">litigation</font> to enforce our     <font color="blue"><font color="blue"><font color="blue">intellectual</font> property</font> rights</font> or to defend our <font color="blue"><font color="blue">patents against</font> challenge</font>     could be expensive and time consuming and <font color="blue">could divert</font> our <font color="blue">management</font>’s     attention</td>
    </tr>
    <tr>
      <td>We may not have <font color="blue">sufficient resources</font> to enforce our <font color="blue">intellectual</font>     <font color="blue">property rights</font> or to defend our <font color="blue">patents against</font> a challenge</td>
    </tr>
    <tr>
      <td>In addition, certain product categories, including <font color="blue">pedicle screws</font>,     have been the subject of <font color="blue">significant</font> <font color="blue">litigation</font> in <font color="blue">recent years</font></td>
    </tr>
    <tr>
      <td>Since we     sell <font color="blue">pedicle screws</font> and <font color="blue">recently introduced</font> our SpheRx <font color="blue">pedicle screw system</font>,     any related <font color="blue">litigation</font> could harm our business</td>
    </tr>
    <tr>
      <td>25       _________________________________________________________________    [78]Table of <font color="blue">Contents       </font>      The medical device industry is <font color="blue">characterized by</font> the existence of a     large number of patents and frequent <font color="blue">litigation</font> <font color="blue">based on</font> allegations of     <font color="blue">patent <font color="blue">infringement</font></font></td>
    </tr>
    <tr>
      <td>Patent <font color="blue">litigation</font> can <font color="blue">involve complex</font> factual and legal     questions and its outcome is uncertain</td>
    </tr>
    <tr>
      <td>Any claim relating to <font color="blue">infringement</font>     of patents that is <font color="blue">successfully</font> asserted <font color="blue"><font color="blue">against us</font> may</font> require us to pay     substantial damages</td>
    </tr>
    <tr>
      <td>Even if we were to prevail, any <font color="blue">litigation</font> could be     costly and time-consuming and <font color="blue">would divert</font> the attention of our <font color="blue">management</font>     and <font color="blue">key personnel from</font> our business <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">success will also depend</font>     in  part on our not <font color="blue">infringing patents issued</font> to others, including our     <font color="blue"><font color="blue">competitor</font>s</font> and potential <font color="blue"><font color="blue">competitor</font>s</font></td>
    </tr>
    <tr>
      <td>If our products are found to infringe     the  patents  of others, our <font color="blue">development</font>, <font color="blue">manufacture</font> and sale of such     potential <font color="blue">products could</font> be <font color="blue">severely restricted</font> or prohibited</td>
    </tr>
    <tr>
      <td>In addition,     our <font color="blue"><font color="blue">competitor</font>s</font> may in<font color="blue">dependent</font>ly develop similar <font color="blue">technologies</font></td>
    </tr>
    <tr>
      <td>Because of     the importance of our patent portfolio to our business, we may lose market     share to our <font color="blue"><font color="blue">competitor</font>s</font> if we fail to protect our <font color="blue"><font color="blue">intellectual</font> property</font>     rights</td>
    </tr>
    <tr>
      <td>As the number of entrants into our market increases, the <font color="blue">possibility</font>     of a <font color="blue">patent <font color="blue">infringement</font></font> claim <font color="blue"><font color="blue">against us</font> grows</font></td>
    </tr>
    <tr>
      <td>While we make an effort to     ensure  that  our  products do not infringe other parties’ patents and     <font color="blue"><font color="blue">proprietary</font> rights</font>, our products and <font color="blue">methods may</font> be <font color="blue">covered by patents</font> held     by our <font color="blue"><font color="blue">competitor</font>s</font></td>
    </tr>
    <tr>
      <td>In addition, our <font color="blue"><font color="blue">competitor</font>s</font> may assert that future     products we <font color="blue">may market infringe</font> their patents</td>
    </tr>
    <tr>
      <td>A  <font color="blue">patent <font color="blue">infringement</font></font> suit brought <font color="blue">against us</font> or any strategic     partners or licensees may force us or any <font color="blue">strategic partners</font> or licensees to     stop or delay developing, <font color="blue">manufacturing</font> or <font color="blue">selling <font color="blue">potential products</font></font> that     are claimed to infringe a third party’s <font color="blue"><font color="blue">intellectual</font> property</font>, unless that     <font color="blue">party grants us</font> or any <font color="blue">strategic partners</font> or <font color="blue">licensees rights</font> to use its     <font color="blue"><font color="blue">intellectual</font> property</font></td>
    </tr>
    <tr>
      <td>In such cases, we may be required to obtain licenses     to  patents  or  <font color="blue">proprietary</font>  rights of others in order to continue to     <font color="blue">commercialize</font>  our products</td>
    </tr>
    <tr>
      <td>However, we may not be able to obtain any     licenses required under any patents or <font color="blue"><font color="blue">proprietary</font> rights</font> of <font color="blue">third parties</font>     on acceptable terms, or at all</td>
    </tr>
    <tr>
      <td>Even if any <font color="blue">strategic partners</font>, licensees or     we were able to obtain rights to the third party’s <font color="blue"><font color="blue">intellectual</font> property</font>,     these <font color="blue">rights may</font> be non-exclusive, thereby giving our <font color="blue"><font color="blue">competitor</font>s</font> access to     the  same  <font color="blue">intellectual</font>  property</td>
    </tr>
    <tr>
      <td>Ultimately,  we  may  be unable to     <font color="blue">commercialize</font> some of our <font color="blue">potential products</font> or may have to cease some of     our business <font color="blue">operations</font> as a result of <font color="blue">patent <font color="blue">infringement</font></font> claims, which     <font color="blue">could severely harm</font> our business</td>
    </tr>
    <tr>
      <td>We are subject to <font color="blue">litigation</font> regarding <font color="blue">cadavers</font> we purchased that originated     from the <font color="blue">University of California </font>at Los Angeles</td>
    </tr>
    <tr>
      <td>For a period of time, we purchased <font color="blue">cadavers</font> for surgeon training     purposes from a broker who is now being <font color="blue">investigated</font> for his practices in     obtaining those <font color="blue">cadavers</font> from the University of California, Los Angeles, or     UCLA We <font color="blue">previously</font> received inquiries and <font color="blue">document requests from</font> <font color="blue">the FDA     </font>and the State of California regarding this <font color="blue">investigation</font></td>
    </tr>
    <tr>
      <td>Although we have     been informed that we are not a subject of this <font color="blue">investigation</font>, we have been     named  as  a  <font color="blue">defendant</font>,  along  with the <font color="blue">Regents of the University </font>of     California, The David Geffen School of Medicine at UCLA, Ernest V Nelson,     Henry  G  Reid, and Johnson &amp; Johnson, in multiple civil class action     lawsuits  relating  to  the  underlying events</td>
    </tr>
    <tr>
      <td>The lawsuits have been     <font color="blue">consolidated</font>  in  a <font color="blue">single court</font> in the <font color="blue">Superior Court of the State </font>of     California, County of Los Angeles</td>
    </tr>
    <tr>
      <td>The <font color="blue">lawsuits generally</font> allege fraud,     negligence and unfair business practices in <font color="blue">connection</font> with the use and     <font color="blue">distribution</font> of the donated <font color="blue">cadavers</font>, and further allege that the <font color="blue">cadavers</font>     were <font color="blue">improperly sold</font></td>
    </tr>
    <tr>
      <td>These <font color="blue">lawsuits may</font> result in <font color="blue">significant</font> legal fees     and could be a diversion of <font color="blue">management</font>’s time and other resources</td>
    </tr>
    <tr>
      <td>If the     claims contained in the lawsuit are <font color="blue">successfully</font> asserted <font color="blue">against us</font>, our     <font color="blue">financial performance</font> and <font color="blue">cash position could</font> be <font color="blue">negatively</font> impacted and the     <font color="blue">market price</font> of our <font color="blue">shares may decline</font></td>
    </tr>
    <tr>
      <td>If we become subject to <font color="blue">product liability</font> claims, we may be required to pay     damages that exceed our <font color="blue">insurance coverage</font></td>
    </tr>
    <tr>
      <td>Our business <font color="blue">exposes us</font> to potential <font color="blue">product liability</font> claims that are     inherent in the testing, <font color="blue">manufacture</font> and sale of <font color="blue">medical devices</font> for spine     <font color="blue">surgery procedures</font></td>
    </tr>
    <tr>
      <td>Spine surgery involves <font color="blue">significant</font> risk of serious     <font color="blue">complications</font>, including bleeding, nerve injury, paralysis and even death</td>
    </tr>
    <tr>
      <td>In addition, we sell <font color="blue"><font color="blue">allograft implant</font>s</font>, derived from cadaver bones, which     pose  the  potential  risk  of  biological  <font color="blue">contamination</font></td>
    </tr>
    <tr>
      <td>If any such     <font color="blue">contamination</font> is found to exist, sales of allograft <font color="blue">products could</font> decline</td>
    </tr>
    <tr>
      <td>26       _________________________________________________________________    [79]Table of <font color="blue">Contents       </font>      Currently, we maintain <font color="blue">product liability</font> insurance in the amount of     dlra10 million</td>
    </tr>
    <tr>
      <td>Any <font color="blue">product liability</font> claim brought <font color="blue">against us</font>, with or without     merit, could result in the increase of our <font color="blue">product liability</font> insurance rates     or the <font color="blue">inability</font> to <font color="blue">secure coverage</font> in the future</td>
    </tr>
    <tr>
      <td>In addition, if our     <font color="blue">product liability</font> insurance proves to be inadequate to pay a <font color="blue">damage award</font>,     we may have to pay the <font color="blue">excess out</font> of our <font color="blue">cash reserves</font>, if <font color="blue">such reserves</font> are     not sufficient, which may harm our <font color="blue">financial condition</font></td>
    </tr>
    <tr>
      <td>If longer-term     patient results and experience indicate that our products or any component     cause tissue damage, motor impairment or other <font color="blue">adverse effects</font>, we could be     subject to <font color="blue">significant</font> liability</td>
    </tr>
    <tr>
      <td>Finally, even a meritless or <font color="blue">unsuccessful</font>     <font color="blue">product liability</font> claim could harm our reputation in the industry, lead to     <font color="blue">significant</font> legal fees and could result in the diversion of <font color="blue">management</font>’s     <font color="blue">attention from managing</font> our business</td>
    </tr>
    <tr>
      <td>Any claims relating to our making <font color="blue">improper payments</font> to physicians for     <font color="blue">consulting services</font>, or other <font color="blue">potential violations</font> of <font color="blue">regulations</font> governing     <font color="blue">interactions between us</font> and healthcare providers, could be time consuming     and costly</td>
    </tr>
    <tr>
      <td>We <font color="blue">frequently</font> engage <font color="blue">spine surgeons</font> as consultants to <font color="blue">assist us with</font>     <font color="blue">scientific research</font> and <font color="blue">development</font> and to help us evaluate <font color="blue">technologies</font></td>
    </tr>
    <tr>
      <td>We     are  subject  to  federal and state laws and <font color="blue">regulations</font> governing our     <font color="blue">relationships with physicians</font> and other <font color="blue"><font color="blue">health care</font> providers</font></td>
    </tr>
    <tr>
      <td><font color="blue">In April     </font>2005, the <font color="blue">United States </font><font color="blue">Department of Justice </font>expanded its <font color="blue">investigation</font>     into the <font color="blue">relationships between medical</font> device companies and <font color="blue">health care</font>     providers</td>
    </tr>
    <tr>
      <td>The <font color="blue">investigation</font> originally appeared to focus on Medtronic     Sofamor Danek, Inc, but the <font color="blue">Department of Justice </font>has <font color="blue">apparently since</font>     <font color="blue">issued subpoenas</font> to DePuy Spine, Inc, a Johnson &amp; Johnson company, Biomet,     Smith &amp;  Nephew,  Stryker  and  Zimmer Holdings, all orthopedic device     <font color="blue"><font color="blue">manufacture</font>rs</font>, relating to the <font color="blue">consulting process</font> and <font color="blue">procedures tied</font> to     fees that <font color="blue">such companies</font> have paid to <font color="blue">physicians as consultants</font></td>
    </tr>
    <tr>
      <td>Although we     have not been contacted by the <font color="blue">Department of Justice </font>in respect of this     <font color="blue">investigation</font>, we could become a subject of the <font color="blue">investigation</font> and be forced     to incur <font color="blue">significant</font> costs as a result</td>
    </tr>
    <tr>
      <td>The <font color="blue">regulations</font> governing the <font color="blue">interactions between medical</font> device     companies and <font color="blue"><font color="blue">health care</font> providers</font> continue to evolve</td>
    </tr>
    <tr>
      <td><font color="blue">Compliance </font>with     these <font color="blue">regulations</font> is costly, especially as accepted methods of compliance     are developed</td>
    </tr>
    <tr>
      <td>We expect to continue to <font color="blue">incur costs</font> related to compliance     with these new measures, such as the <font color="blue">requirement</font> to <font color="blue">comply with</font> the new     <font color="blue">California Prescription Drug Marketing Act</font></td>
    </tr>
    <tr>
      <td>We or our suppliers may be the subject of claims for non-<font color="blue">compliance with</font> FDA     <font color="blue">regulations</font> in <font color="blue">connection</font> with the processing or <font color="blue">distribution</font> of allograft     implants</td>
    </tr>
    <tr>
      <td>It is possible that <font color="blue">allegations may</font> be made <font color="blue">against us</font> or against     <font color="blue">donor recovery groups</font> or tissue banks, including those with which we have a     <font color="blue">contractual</font> relationship, claiming that the <font color="blue">acquisition</font> or processing of     tissue  for  allograft  implants  does  not <font color="blue">comply with</font> applicable FDA     <font color="blue">regulations</font> or other <font color="blue">relevant statutes</font> and <font color="blue">regulations</font></td>
    </tr>
    <tr>
      <td><font color="blue">Allegations </font>like     these could cause <font color="blue">regulators</font> or other <font color="blue">authorities</font> to take <font color="blue">investigative</font> or     other action <font color="blue">against us</font>, or could cause <font color="blue">negative publicity</font> for us or our     <font color="blue">industry generally</font></td>
    </tr>
    <tr>
      <td>These actions or any <font color="blue">negative publicity</font> could cause us     to incur substantial costs, divert the attention of our <font color="blue">management</font> from our     business, harm our reputation and cause the <font color="blue">market price</font> of our shares to     decline</td>
    </tr>
    <tr>
      <td>Risks Related to the Securities Markets and Ownership of Our Common Stock       We expect that the price of our <font color="blue">common stock</font> will fluctuate substantially,     potentially <font color="blue"><font color="blue">adversely</font> affect</font>ing the ability of investors to sell their     shares</td>
    </tr>
    <tr>
      <td>The <font color="blue">market price</font> of our <font color="blue">common stock</font> is likely to be volatile and may     <font color="blue">fluctuate substantially due</font> to many factors, including:         •  volume and timing of orders for our products;         •  the <font color="blue">introduction</font> of <font color="blue">new products</font> or <font color="blue">product <font color="blue"><font color="blue">enhancement</font>s</font></font> by us or our     <font color="blue"><font color="blue">competitor</font>s</font>;         •  disputes or other <font color="blue">development</font>s with respect to <font color="blue"><font color="blue">intellectual</font> property</font>     rights or other <font color="blue">potential legal actions</font>;                                         27       _________________________________________________________________    [80]Table of <font color="blue">Contents       </font>  •  our ability to develop, obtain <font color="blue"><font color="blue">regulatory</font> clearance</font> or approval for,     and <font color="blue">market new</font> and enhanced <font color="blue">products on</font> a <font color="blue">timely basis</font>;         •  <font color="blue">quarterly variations</font> in our or our <font color="blue">competitor</font>’s results of <font color="blue">operations</font>;         •  sales of large blocks of our <font color="blue">common stock</font>, including sales by our     <font color="blue">executive officers</font> and <font color="blue">directors</font>;         •  <font color="blue">announcements</font> of <font color="blue">technological</font> or <font color="blue">medical innovations</font> for the treatment     of <font color="blue">spine pathology</font>;         •  changes in <font color="blue">government</font>al <font color="blue">regulations</font> or in the status of our <font color="blue">regulatory</font>     approvals, <font color="blue">clearances</font> or <font color="blue"><font color="blue">application</font>s</font>;         •  changes in the <font color="blue">availability</font> of third-party <font color="blue">reimbursement</font> in the United     States or other countries;         •  the <font color="blue">acquisition</font> or <font color="blue">divestiture</font> of products, assets or <font color="blue">technology</font>;          •   changes  in earnings estimates or <font color="blue">recommendations</font> by securities     analysts; and          •   general  <font color="blue">market conditions</font> and other factors, including factors     unrelated to our operating performance or the operating performance of our     <font color="blue"><font color="blue">competitor</font>s</font></td>
    </tr>
    <tr>
      <td>Market  price fluctuations may <font color="blue">negatively</font> affect the ability of     investors to sell our <font color="blue">shares at consistent prices</font></td>
    </tr>
    <tr>
      <td>Recent changes in the required <font color="blue">accounting treatment</font> for <font color="blue">stock options will</font>     have a material <font color="blue">negative impact on</font> our <font color="blue">financial statements</font> and may affect     our stock price</td>
    </tr>
    <tr>
      <td><font color="blue">In December </font>2004, the Financial Accounting Standards Board, or FASB,     issued SFAS Nodtta 123R, pursuant to which we must measure all stock-based     <font color="blue">compensation awards</font>, including grants of employee stock options, using a     fair  value-based  method  and <font color="blue">record such expense</font> in our <font color="blue">consolidated</font>     <font color="blue">financial statements</font></td>
    </tr>
    <tr>
      <td>Currently, we disclose <font color="blue">such expenses on</font> a pro forma     basis in the notes to our <font color="blue">consolidated</font> <font color="blue">financial statements</font>, but we do not     record  a  charge  for  <font color="blue">employee stock option expense</font> in the financial     statements</td>
    </tr>
    <tr>
      <td>We <font color="blue">began complying with</font> SFAS Nodtta 123R as of January 1, 2006; as     a result our reported earnings will decrease, which may affect our stock     price</td>
    </tr>
    <tr>
      <td>We <font color="blue">may become involved</font> in securities class action <font color="blue">litigation</font> that could     divert <font color="blue">management</font>’s attention and harm our business</td>
    </tr>
    <tr>
      <td>The <font color="blue">stock market</font> in general, the <font color="blue">Nasdaq National Market </font>and the market     for medical device companies in particular, has experienced <font color="blue">extreme price</font>     and <font color="blue">volume fluctuations</font> that have often been unrelated or <font color="blue">disproportionate</font>     to the operating performance of those companies</td>
    </tr>
    <tr>
      <td>Further, the <font color="blue">market price</font>s     of securities of medical device companies have been <font color="blue">particularly</font> volatile</td>
    </tr>
    <tr>
      <td>These <font color="blue">broad market</font> and industry factors may <font color="blue">materially</font> harm the <font color="blue">market price</font>     of our <font color="blue">common stock</font>, regardless of our operating performance</td>
    </tr>
    <tr>
      <td>In the past,     following  periods  of  <font color="blue">volatility</font> in the <font color="blue">market price</font> of a particular     company’s securities, securities class action <font color="blue">litigation</font> has often been     brought  against  that company</td>
    </tr>
    <tr>
      <td>We <font color="blue">may become involved</font> in this type of     <font color="blue">litigation</font>  in  the  future</td>
    </tr>
    <tr>
      <td><font color="blue">Litigation </font>often is expensive and diverts     <font color="blue">management</font>’s  attention and resources, <font color="blue">which could</font> <font color="blue">materially</font> harm our     <font color="blue">financial condition</font> and results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Anti-takeover provisions in our organizational documents and <font color="blue">Delaware </font>law     <font color="blue">may discourage</font> or prevent a change of control, even if an <font color="blue">acquisition</font> would     be <font color="blue">beneficial</font> to our <font color="blue">stockholders</font>, <font color="blue">which could</font> affect our stock price     <font color="blue">adversely</font> and <font color="blue">prevent attempts by</font> our <font color="blue">stockholders</font> to replace or remove our     current <font color="blue">management</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">certificate</font> of <font color="blue">incorporation</font> and <font color="blue">bylaws contain provisions</font> that     <font color="blue">could delay</font> or prevent a change of control of our company or changes in our     board of <font color="blue">directors</font> that our <font color="blue">stockholders</font> might consider favorable</td>
    </tr>
    <tr>
      <td>Some of     these provisions:         •  authorize the issuance of preferred stock which can be created and     issued by the board of <font color="blue">directors</font> without prior stockholder approval, with     rights senior to those of the <font color="blue">common stock</font>;                                         28       _________________________________________________________________    [81]Table of <font color="blue">Contents       </font>  •  provide for a <font color="blue">classified board</font> of <font color="blue">directors</font>, with each director serving     a staggered three-year term;         •  prohibit our <font color="blue">stockholders</font> from filling board vacancies, calling special     <font color="blue">stockholder meetings</font>, or taking <font color="blue">action by written consent</font>;          •   prohibit  our  <font color="blue">stockholders</font>  from making certain changes to our     <font color="blue">certificate</font> of <font color="blue">incorporation</font> or bylaws except with 66^2/3prca stockholder     approval; and         •  require <font color="blue">advance written</font> notice of <font color="blue">stockholder proposals</font> and director     <font color="blue">nominations</font></td>
    </tr>
    <tr>
      <td>In addition, we are subject to the provisions of Section 203 of the     <font color="blue">Delaware </font> General Corporation Law, <font color="blue">which may prohibit certain</font> business     <font color="blue">combination</font>s with <font color="blue">stockholders</font> owning 15prca or more of our <font color="blue">outstanding voting</font>     stock</td>
    </tr>
    <tr>
      <td>These and other provisions in our <font color="blue">certificate</font> of <font color="blue">incorporation</font>, our     bylaws and <font color="blue">Delaware </font>law could make it more <font color="blue">difficult</font> for <font color="blue">stockholders</font> or     <font color="blue">potential acquirers</font> to obtain control of our board of <font color="blue">directors</font> or initiate     actions that are <font color="blue">opposed by</font> our then-current board of <font color="blue">directors</font>, including     delay or impede a merger, tender offer, or <font color="blue">proxy contest involving</font> our     company</td>
    </tr>
    <tr>
      <td>Any delay or prevention of a change of <font color="blue">control transaction</font> or     changes in our board of <font color="blue">directors</font> could cause the <font color="blue">market price</font> of our common     stock to decline</td>
    </tr>
    <tr>
      <td>We do not intend to <font color="blue">pay <font color="blue">cash dividends</font></font></td>
    </tr>
    <tr>
      <td>We have never declared or <font color="blue">paid <font color="blue">cash dividends</font> on</font> our <font color="blue">capital stock</font></td>
    </tr>
    <tr>
      <td>We     <font color="blue">currently intend</font> to retain all <font color="blue">available funds</font> and any <font color="blue">future earnings</font> for     use in the operation and expansion of our business and do not anticipate     paying any <font color="blue">cash dividends</font> in the <font color="blue">foreseeable future</font></td>
    </tr>
    <tr>
      <td>In addition, the terms     of  any <font color="blue">future debt</font> or credit <font color="blue">facility</font> may preclude us from paying any     dividends</td>
    </tr>
    <tr>
      <td>As a result, capital <font color="blue">appreciation</font>, if any, of our <font color="blue">common stock</font>     will be our <font color="blue">stockholders</font>’ source of <font color="blue">potential gain</font> for the foreseeable     future</td>
    </tr>
  </tbody>
</table>